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Zusammenfassung 
Der vorzeitige Blasensprung vor der 37 Schwangerschaftswoche, tritt in ungefähr 1 % 
aller Schwangerschaften auf und ist die Ursache von 30-40 % aller Frühgeburten. Der 
vorzeitige Blasensprung ist somit eine der wichtigsten Ursachen für eine Frühgeburt. 
Sowohl der vorzeitige Blasensprung als auch die Frühgeburt erhöhen das Risiko der 
mütterlichen Morbidität sowie der neugeborenen Morbidität und Mortalität. 
Verschiedene Therapien für einen vorzeitigen Blasensprung sind vorgeschlagen und in 
menschlichen, fötalen Membranmodellen getestet worden. Bisher hat aber keine dieser 
Therapieversuche den Sprung in die klinische Praxis geschafft. 
Das Ziel dieser Arbeit war es, eine alternative Therapieoption für den vorzeitigen 
Blasensprung mittels einer durch Tissue-Engineering hergestellten Matrix zu 
entwickeln. Diese Matrix sollte die natürliche Struktur des Amnions imitieren. 
Zu Beginn der Arbeit wurde eine reproduzierbare Methodik etabliert, welche die 
Extraktion und Expansion von humanen Amnionepithel- und Amnionmesenchymzellen 
von Früh- und Termingeburten zulässt. In einem in vitro Wundheilungstest, wurde 
gezeigt, dass das Reparaturpotential von humanen Amnionepithel- und 
Amnionmesenchymzellen sowie die Reaktion auf verschiedene, Zellteilung 
stimulierende Faktoren, vom Gestationsalter abhängig ist. Besonders 
Amnionmesenchymzellen von Frühgeburten zeigen im Vergleich zu 
Amnionmesenchymalzellen von Termingeburten ein zweifach gesteigertes 
Reparaturpotential. Die Proliferation von Amnionmesenchymzellen, die aus 
Frühgeburten extrahiert wurden, konnte mittels Platelet Derived Growth Factor und 
Tumor Necrosis Factor α verdoppelt werden. Zum Abschluss der Arbeit wurden 3D 
  
Fibrinmatrices als Gerüste für isolierte Amnionepithel- und Amnionmesenchymzellen 
von Frühgeburten verwendet. Amnionmesenchymzellen wurden in die Fibrinmatrix 
eingebettet und Amnionepithelzellen wurden auf diese Matrix plaziert. Diese 
Architektur ähnelt sehr der natürlichen Struktur des Amnions. Durch Hinzufügung von 
spezifischem extrazellulären Matrixmolekülen (Kollagen I, Laminin-1 oder 
Fibronektin), welche die Zelladhäsion vermitteln konnten die biologischen 
Eigenschaften der Fibrinmatrices verändert werden. Ausserdem stimulierten 
verschiedene extrazelluäre Matrixmoleküle den Matrixabbau durch zellgebundene 
Proteasen: Matrix Metalloproteasen oder Serinproteasen (zum Beispiel Plasmin). Es 
wurde gezeigt, dass Amnionepithel- und Amnionmesenchymzellen von Frühgeburten in 
solchen modifizierten 3D Fibrinmatrices ihre natürliche Morphologie und 
Lebensfähigkeit behalten. Ausserdem wurde Kollagen I als Grundgerüst für eine 3D 
Matrix untersucht. Ein wesentliches Problem in diesem Modell war die Schrumpfung 
und folglich die Grössenreduktion der Kollagen I Matrix in vitro. In vivo würde eine 
solche Schrumpfung eines Implantates zu einem unvollständigen Amnionverschluss mit 
den entsprechenden klinischen Konsequenzen führen. Im Gegensatz zur Kollagen I 
Zellmatrix ergab eine Fibrin basierte Zellmatrix in vitro während einer Woche keine 
Schrumpfung.  
Die Daten dieser Arbeit, lassen vermuten, dass fibrinbasierte Zellmatrix-Systeme bei 
der Transplantation von Amnionzellen nützlich sein könnten. Jedoch müssen diese 
Daten als vorläufig betrachtet werden. Die nächsten Untersuchungen zielen nun 
daraufhin, dies mittels Tissue-Engeneering hergestellten Amnionzelltransplatate unter 
komplizierteren, multifaktoriellen Bedingungen zu testen. 
  
Summary 
Premature rupture of the membranes occurring before 37 weeks’ gestation is usually 
referred to as preterm premature rupture of the membranes (PPROM). PPROM occurs 
in approximately 1 % of all pregnancies and is associated with 30-40 % of preterm 
deliveries. It is the leading single identifiable cause of preterm delivery known so far. 
Both PPROM and preterm birth carry a high risk of maternal morbidity and neonatal 
morbidity and mortality. Several treatments for PPROM in human fetal membrane 
models have been proposed but none of these treatments have yet been introduced into 
clinical routine. 
This thesis focuses on a strategy to develop a potential option for the treatment of 
PPROM patients based on a tissue engineering approach. In particular, this approach 
relies on the design of a cell containing matrix that mimics the architecture of native 
amnion.  
First, a reproducible methodology that permits to collect and expand human amnion 
epithelial and mesenchymal cells from preterm and term placenta was established. 
Furthermore, using an in vitro lesion repair assay, it was demonstrated that the repair 
potential of human amnion epithelial and mesenchymal cells as well as their reaction 
towards different proliferation stimulants depends on the gestational age. Especially, 
preterm amnion mesenchymal cells showed approximately two fold increased repair 
potential compared to their term counterparts. Moreover, an increase in the proliferation 
of preterm amnion mesenchymal cells was found after treatment with platelet derived 
growth factor and tumor necrosis factor α. Furthermore, 3D fibrin matrices were used as 
a scaffold for isolated preterm amnion epithelial and mesenchymal cells.
   
As outlined in this thesis, an interesting refinement of the here introduced 3D fibrin-
matrix system could be the addition of specific peptide sequences involved in cell 
adhesion and/or migration, and being degradable by cell-associated proteases such as 
matrix metalloproteinases or serine proteases such as plasmin. It was demonstrated that 
preterm amnion epithelial and mesenchymal cells in modified 3D fibrin based cell-
matrix systems acquired their natural morphologies and displayed viability. 
Furthermore, the use of collagen I as a scaffold matrix was also investigated in this 
work. Limitations of this approach include contraction and consequently size reduction 
of collagen I matrices in vitro. In vivo such size reduction would inevitably induce 
failure of the implant followed by severe clinical consequences. In contrast to collagen I 
matrix-cell systems, no decrease in size of fibrin cell-matrix systems was observed over 
the time course of one week, suggesting also size stability for in vivo use. 
Related to this data, one might speculate, that such fibrin based cell-matrix systems may 
be useful in amnion cell transplantation. However, these data are clearly preliminary 
and have to be confirmed by exposure of amnion cell-based tissue engineered grafts to 
more complex multifactorial in vivo conditions. 
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Background 
 
All verterbrates have accessory extra-embryonic tissues enclosing the fetus, known 
collectively as the fetal membranes. These tissues comprise the three primary germ 
layers that are not innervated. These layers only exist as embryonic accessories. They 
are genetically identical to the fetus, but have a limited life time, existing only until the 
fetus is developed sufficiently for it to become a functional individual. The embryonic 
development of the fetal membranes begins as soon as the blastocyst implants into the 
maternal endometrium. Most of the blastocyst’s cells constitute the outer wall 
(trophoblast), surrounding the blastocyst cavity. Generally speaking, the trophoblast is 
the preceding tissue to the fetal membranes, including the placenta. The inner cell mass, 
a small group of larger cells that form the embryoblast, is apposed to the inner surface 
of the trophoblastic vesicle. The embryo, the umbilical cord, and amnion are derived 
from these cells. During attachment and after invasion of the endometrial epithelium, 
the trophoblastic cells of the implanting embryonic pole of the blastocyst show 
increased proliferation, resulting in a double-layered trophoblast. The outer of the two 
layers directly facing the maternal tissue, is transformed to a syncytiotrophoblast by 
fusion of neighbouring trophoblast cells. The remaining cellular components of the 
blastocyst wall, which have not yet achieved contact to maternal tissues are called 
cytotrophoblast. Between day 13 and 14 post coitus, the cytotrophoblast proliferates to 
form cellular columns invading the syncytiotrophoblast (primary villi). Further 
proliferation and branching results in the formation of the secondary and tertiary villi 
(Figure 1). The network of branching villi suspends the chorion cavity of the 
endometrium. Further expansion obliterates the capillaries and leads to degeneration of 
the villi in the chorion and the chorion becomes smooth (chorion leave). 
Simultaneously, there is proliferation of villi at the decidua basalis, where the fetal part 
of the placenta arises (chorion frondosum). The ‘chorion leave’ is usually considered as 
synonymous for ‘membranes’ and is distinct from the ‘chorion frondosum’, which is 
actually placental tissue.  
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Fetal membranes are highly specialized areas of maternal-fetal interactions, which 
appear to have achieved greater significance in the higher vertebrates for the survival of 
the pregnancy, as well as for parturition1. The extraplacental fetal membranes, amnion 
and chorion, have also been described as individual membranes2, 3 (Figure 2). 
 
 
Figure 1. Simplified drawings of typical stages of early placental development. (a&b) 
Prelacunar stages. (c) Lacunar stage. (d) Transition from lacunar to primary villous 
stage. E=endometrial epithelium; EB=embryoblast; CT=cytotrophoblast; 
ST=syncytiotrophoblast; EM=extraembrionic mesoderm; CP=primary chorionic plate; 
T=trabeculae and primary villi; L=maternal blood lacunae; TS=trophoblastic shell; 
EV=endometrial vessel; D=deciduas; PB=placental bed. Adopted from Benirschke and 
Kaufmann (1990)1. 
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Figure 2. Photograph of a sagittal section of a uterus containing a fetus. Adapted from 
Boyd (1970)4. 
 
 
Structure of human fetal membranes 
 
Measuring only 0.08 to 0.12 mm in thickness, the human amnion is composed of five 
morphologically distinct layers (Figure 3). It contains no blood vessels or nerves; the 
nutrients it requires are supplied directly by diffusion out of amniotic fluid and/or from 
the underlining decidua. The innermost layer, nearest to the fetus, is named amniotic 
epithelium. Amniotic epithelial cells secrete collagen types III and IV and 
noncollagenous glycoproteins (laminins, nidogen, and fibronectin) that form a basement 
membrane. This basement membrane constitutes the second layer of the amnion. The 
basement membrane provides a solid support for amniotic epithelial cells. The compact 
layer of connective tissue adjacent to the basement membrane forms the main fibrous 
skeleton of the amnion. The collagens of the compact layer are secreted by 
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mesenchymal cells situated in the fibroblast layer. Interstitial collagens (types I and III) 
predominate and form parallel bundles that maintain the mechanical integrity of the 
amnion. Collagen types V and VI form filamentous connections between interstitial 
collagens and the epithelial basement membrane. The fibroblast layer is the thickest of 
all amniotic layers. The intermediate layer (spongy layer, or zona spongiosa) lies 
between amnion and chorion. Its abundant content of proteoglycans and glycoproteins 
produces a ‘spongy’ appearance in histologic preparations, and it contains a nonfibrillar 
meshwork of mostly type III collagen. The intermediate layer adsorbs physical stresses 
by permitting the amnion to slide relative to the underlying chorion, which is firmly 
adherent to the maternal decidua. Although the chorion (0.04 to 0.4 mm in thickness) is 
approximately 4 times thicker than the amnion, the amnion has greater tensile strength. 
The chorion resembles a typical epithelial membrane, with its polarity directed towards 
the maternal decidua. As pregnancy progresses, trophoblastic villi within the chorionic 
layer of the fetal membranes that are free of the placenta, regress5.  
 
 
Figure 3. Schematic representation of the structure of the fetal membranes at term. The  
extracellular-matrix composition of each layer is shown. Adopted from Parry et al. 
(1998)5. 
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Human amnion epithelial and mesenchymal cells 
Early in embryogenesis, i.e. before 8 weeks of gestation, the amnion membrane is 
comprised of a layer of epithelial cells (presumably derived from the fetal ectoderm) 
and a separate layer of mesenchymal cells (presumably derived from the fetal 
mesoderm) that lie immediately adjacent to the epithelial cells. At this early stage of 
embryogenesis, there are approximately equal numbers of amnion epithelial and 
mesenchymal cells. As the amniontic sac expands, the epithelial cells replicate at a rate 
sufficient to maintain a continuous layer of epithelium. The cells are connected by 
desmosomes. The rate of replication of the mesenchymal cells, however, apparently 
does not keep pace with the expansion of the amniontic sac. By 10-14 weeks gestation, 
these fibroblast-like cells begin to be dispersed, ultimately being connected only by a 
loose lattice of connective tissue. During the third trimester of pregnancy, there are, on 
average, only about one-tenth as many mesenchymal as epithelial cells6.  
Human amnion epithelial cells are immunologically naïve because they do not express 
any of the leukocyte antigens (HLA)-A, -B, -C or –DR7. Immune reaction did not occur 
after transplantation in volunteers8. Since then, amniotic tissue has been used for 
allotransplantation to treat patients with chronic sphingomyelinase deficiency9 and 
lysosomal storage disease10. In addition, it has already been reported that human amnion 
epithelial cells may have a significant role in supplying neurotrophic factors as well as 
neurotransmitters to the amniotic fluid, suggesting an important function in the early 
stages of neural development of the embryo. Human amnion epithelial cells present 
immunological markers for neurons, astrocytes and oligodendrocytes, as they synthesize 
and release acetylcholine and catecholamine as well as express mRNA encoding for 
dopamine receptors and transporters10. 
Almost all studies describing amnion cellular function have been conducted with 
amnion epithelial cells, however, amnion mesenchymal cells have largely been ignored. 
There is no clarity concerning the immunogenicity of amnion mesenchymal cells, since 
transplantation studies have never been performed. Recently, it has been shown that 
some critical functions of the amnion are performed by mesenchymal cells. For 
example, interstitial collagens that provide the strength of the amnion are synthesized 
and processed exclusively in mesenchymal cells. The enzyme lysyl oxidase, which 
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catalyses the initial reaction in the cross-linking of interstitial collagen fibrils, is also 
expressed primarily in these cells. Furthermore, the mesenchymal cells are the major 
source of tissue inhibitor of metalloproteinase-1 (TIMP-1), cytokines and produces 
keratinocyte growth factor (KGF) which is involved in wound repair11. 
 
 
 
Functions of human fetal membranes 
 
Human pregnancy and parturition present a unique set of challenges for fetal 
membranes, which form an adjustable biomechanical container for a large growing and 
moving of fetus12. Sufficient strength and elasticity are needed to withstand slow but 
progressive stretching to approximately double their size by term and simultaneously to 
protect against rapid pressure on the maternal abdomen. The spongy layer is rich in 
proteoglycans which contains >90 % water and swell, allowing the amnion to slide 
relative to the chorion. Amnion and chorion retain amniotic fluid, secrete substances 
both into the amniotic fluid and towards the uterus. The fetal membranes allow passive 
diffusion of electrically neutral, lipophilic substances, oxygen, electrolytes and water. 
Certain constituents, such as amino acids, iron, calcium, and phosphorus, enter by active 
transport. Glucose penetrates by facilitated diffusion13. Furthermore, the membranes 
protect the fetus against infections ascending the reproductive tract. During the 
pregnancy the major functions of amnion and chorion are maintenance and protection of 
the fetus, however at the end of the pregnancy, the fetal membranes must undergo 
planned degradation allowing the delivery of the fetus at term. The membranes need to 
be receptive to endocrine and paracrine signals from mother, fetus and the materno-fetal 
interface.  
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Rupture of human fetal membranes 
 
Fetal membranes normally rupture during labour (uterine contraction). For most 
pregnancies, labour starts at 38-42 weeks gestation in the presence of intact membranes. 
The events leading to fetal membrane weakening and rupture at term are not fully 
understood. A cascade of events involving mechanical membrane distortion, 
extracellular matrix distortion with loss of cell-matrix interactions, apoptosis, MMP-
activation, and membrane degradation has been proposed and is supported by ample 
experimental material5, 14. Rupture at term before the onset of regular labour is defined 
as premature rupture of membranes (PROM). It takes place in some 8-10 % of 
pregnancies. Premature rupture of the membranes occurring before 37 weeks’ gestation 
is usually referred to as preterm premature rupture of the membranes (PPROM). 
PPROM occurs in approximately 1 % of all pregnancies and is associated with 30-40 % 
of preterm deliveries. It is thus the leading single identifiable cause of preterm delivery5. 
High fetal morbidity and mortality rates occur with PPROM because of infection, 
premature labor, fetal compromise from umbilical cord compression, and/or fetal 
deformation (pulmonary hypoplasia and/or arthrogryposis). Maternal complications are 
also more common with PPROM, including chorioamnionitis rates as high as 25-35 
%15.  
The term iatrogenic PPROM (iPPOM) was induced to describe PPROM as a result of 
an invasive intrauterine procedure like amniocentesis or fetoscopy, during which, by 
definition, the amnion cavity is entered and therefore the membranes disrupted16. 
iPPROM is a major limitation of uterine endoscopy. The incidence of iPPROM is 10 % 
after laser coagulation for twin-to-twin transfusion syndrome17, >30 % after fetoscopic 
cord ligation18 and >62 % after endoscopic tracheal clipping19. Despite advances in 
perinatal care, PROM and PPROM continue to be important obstetrical complications. 
The cause of premature rupture of the fetal membranes is almost certainly multifactorial 
(Figure 4). Traditionally, rupture of the fetal membranes has been attributed to 
increasing physical stresses that weaken the membranes. At the molecular level, 
premature rupture of the membranes appears to result from diminished collagen 
synthesis, altered collagen structure, and accelerated collagen degradation, possibly in 
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association with concurrent cellular changes within the fetal membranes. These 
hypotheses are not mutually exclusive, and biophysical stresses may amplify these 
biochemical changes5. 
 
 
Figure 4. Schematic diagram of various mechanisms that have been proposed to result 
in PROM or PPROM. Taken from Parry et al. (1998)5. 
 
 
Fetal membranes: healing and sealing 
 
Spontaneous wound healing in fetal membranes 
Knowledge about the healing potential of fetal membranes has long been limited to case 
reports related to iatrogenic rupture after amniocentesis. Older case-reports mention the 
presence of defects in the fetal membrane several weeks after invasive procedures20, 21. 
However, most cases of post-amniocentesis amniorrehexis are self-limited, resealing 
spontaneously with favourable pregnancy outcomes22, 23. Resealing of the membranes 
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following spontaneous PPROM (sPPROM) is less frequent and occurs in only 7.7 to 9.7 
% of cases24, 25. This suggests that the fetal membranes have the capacity under certain, 
very individual conditions to heal a created or spontaneously occurring defect. 
However, the defect might be concealed or the membrane could re-seal through 
retraction, sliding, contraction and scarring in the myometrial and decidual layers of the 
uterus, rather than involving an active healing mechanism at the level of the fetal 
membranes26.  
 
 
Surgical sealing of fetal membranes: Clinical approaches 
Actual expectant management of PROM differs from institution to institution and 
includes immediate delivery or termination of pregnancy versus conservative 
management with or without the use of tocolytics and steroids in various 
combinations27. 
Several methods for sealing and healing of human fetal membrane defects have been 
proposed, but clinical series are small and their successes limited. So far, none of these 
techniques have been introduced into routine clinical practice28. 
One of the first case reports refers to the successful application of maternal blood to the 
amnion leakage under ultrasonographic guidance to produce a clot patch. Leakage 
stopped within 12 h and ultrasonographic investigation showed that the blood clot was 
gradually diminished and completely disappeared within 3 weeks29. A healthy baby was 
born at term. This was an individual case and the application was performed in a patient 
with iPPROM following amniocentesis at 16 weeks gestation.  
Some cases of apparent successful sealing of fetal membranes were reported after 
iPPROM with a proportion of platelets injected transabdominally into the amniotic 
cavity along with a proportion of cryoprecipitates (so-called amniopatch)30, 31. This was 
the first successful treatment of iPPROM in a case with persistent amniotic fluid 
leakage following fetoscopy at 18 weeks of gestation. The hypothesis was that platelets 
became activated at the rupture site and fibrin clot formation would initiate the healing 
process. Such a procedure would first allow the membranes to seal and then to be 
restored by surrounding amnion cells. However the detailed mechanism by which this 
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amnion patch was successful is not understood, since the amnion patch was injected 
into the amniotic cavity without being aware of the exact localisation of the rupture. It is 
not clear how the material could find its own way to the defect and seal it. 
In this context, the interaction between platelets and the fetal membranes has been 
studied in vitro32. It was found that exposed connective tissue of amniotic membranes 
triggered platelet adhesion, aggregation, as well as activation. Platelets were shown to 
seal a standardized puncture of fetal membranes under a certain pressure. However, it is 
still not clear, whether this platelet-fibrin plug effectively stimulates tissue regeneration 
at the trauma site. Furthermore, the original in vivo reports, mentioned above, have 
some important limitations. Two of the six cases were complicated by sudden 
intrauterine fetal dead. Severe bradycardia and hypotension have been observed 
following platelet transfusion. Thus, it has been hypothesized that hemodynamic 
changes secondary to platelet activation could have caused the fetal demise. Given these 
serious complications, application of amnion patches to seal leakage of fetal membranes 
is not satisfying to allow clinical application. Further experimental work is needed to 
determine the optimal origin, composition, volume and concentration of blood products 
administered.  
Several authors developed strategies to attempt sealing of membranes undergoing 
sPPROM33-37 using fibrin sealants. Fibrin sealants were applied in order to act as a 
cervical plug to stop further amniorrhexis and prevent ascending infections. Inconsistent 
results, small number of cases and poor study design without control groups makes it 
difficult to draw meaningful conclusions. The continuation of that work was a case 
report describing the direct application of a high concentration of maternal platelets and 
fibrin glue to the uterine surface of the damaged amniotic membrane under fetoscopic 
visualization. The envisioned mechanism of the procedure was formation of a platelet-
fibrin plug which acutely blocks further leakage of fluid and may offer a lattice for 
amniocyte migration and final closure38. Doubts have to be expressed on these studies 
since amniorrhexis reappeared weeks after the procedure30.  
In vitro, fibrin glue effectively improved the structural integrity of artificially punctured 
human chorioamniotic membranes. Different fibrin sealant compositions were 
compared for their efficacy to seal a standardized puncture in fetal membranes. 
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Amniotic membranes were best sealed by a fibrin/thrombin-based sealant39. Both, 
fibrinogen and thrombin are required to form a fibrin clot in the final step of the clotting 
cascade. Some in vivo results exist about the transvaginal application of intracervical 
fibrin sealants40. Fibrin tissue sealants were shown to increase the postrupture latency 
period and neonatal survival. The fibrin clot was probably able to seal and interrupt the 
leakage of amniotic fluid, but this was not in all cases accompanied with an increase in 
the amniotic fluid volume. Fibrin sealants may further act as barriers to ascending 
infections, but only in cases where a preliminary placement of a cervical cerclage is 
omitted. Although fibrin sealants promote local growth and tissue repair it is doubtable 
that a direct closure of the membranes has been obtained. 
In a rabbit model fetoscopic access sites were successfully sealed with collagen plugs41. 
The use of collagen plugs in combination with suturing of the myometrial layer resulted 
in functional restoration of the membrane integrity with preservation of amniotic fluid 
and normal fetal pulmonary growth in more than 80 % of the cases. Histological 
examination revealed entrapment of membranes between the plug and the myometrium 
but no anatomic repair of the membranes.  
Gelatine sponges were also used to close fetal membrane defects in vitro42. The primary 
benefit of this material turned out to be the length of time it remained intact within the 
amnion cavity. Gelatine sponges remained longer at the wound site than fibrin or other 
blood products. A similar method was used in sheeps and primates, when gelatine 
sponges were used to maintain membrane integrity after fetoscopy43. The technique was 
furthermore evaluated in vivo, in patients with the poorest outcomes based on 
prognostic factors. After cervical cerclage, a gelatine sponge was administered into the 
amniotic cavity. Within only 30 % surviving infants, the in vitro expectations were not 
confirmed. Major concerns were potential fetal aspiration of the implanted gelatine 
sponge or obstruction of the fetal gastrointestinal tract44, 45. 
The term amnion graft was established by a case report46. It describes a commercial 
collagen plug, placed endoscopically over the membrane defect in a case of spontaneous 
PPROM, followed by fixation with fibrin adhesive. Gluing with fibrin proved quite 
effective but required expansion of the amniotic cavity with carbon dioxide, which can 
further dissect the chorionic space. Endoscopically, the clinical characteristics of the site 
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of rupture suggested that the size, location and shape of the defect were unlikely to be 
healed with an amniopatch. 
Concluding, it has to be pointed out again that all of the mentioned techniques are far 
from being introduced into the routine clinics. Therefore, alternative methods have to be 
explored to manage either sPPROM or iPPROM and to decrease the likelihood of 
miscarriage, preterm delivery and the complication of prematurity. 
 
 
Tissue Engineering - Regenerative Medicine 
 
Tissue engineering is an interdisciplinary field in which the principles and methods of 
engineering combine with those of biological sciences for the fundamental 
understanding of structure-function relationships in normal and pathological tissues and 
organs, as well as for the development of biologic substitutes that can restore, maintain, 
or improve tissue or organ function. More recently, the expression ‘regenerative 
medicine’ has been often used either as a synonym or as an all-embracing branch of 
medical science that would include tissue engineering per se. 
In the current context of tissue engineering, as defined above, new tissues or organs can 
be created through three general strategies, or a combination of them, as follows: 
(1) Infusion of isolated cells, i.e. cells are isolated from donors, expanded and/or 
modified in vitro and re-implanted for the supply of a specific function.  
(2) Tissue-inducing substances. In this process, appropriate signal molecules (e.g. 
growth factors) are delivered to specific targets for the stimulation or control of tissue 
growth or maturation. 
(3) Cells placed on or within performed scaffold (matrices). This methodology consists 
of culturing the cells on or within a natural or synthetic but degradable scaffold matrix 
in vitro and transplantation of the cell-matrix composite at the site where regeneration is 
required. The scaffold material provides initial mechanical support and a template for 
three-dimensional organization. 
All of these strategies can be applied in autologous, heterologous, or xenologous 
manner. They all carry potential problems, enclosing immunologic rejection, growth 
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limitations, differentiation and function restrictions, incorporation barriers and cell or 
tissue delivery difficulties. Despite the limited clinical experience to date, efforts at 
engineering almost every mammalian tissue have already occured47. 
 
Acute wound healing: an example for tissue regeneration 
Healing of an acute wound follows a predictable chain of events. This chain of events 
occurs in a carefully regulated manner that is reproducible from wound to wound. The 
phases of wound healing are overlapping, but are described in a linear fashion for the 
purpose of clarity. The five phases that characterize wound healing include (1) 
hemostasis, (2) inflammation, (3) cellular migration and proliferation, (4) protein 
synthesis and wound contraction, and (5) remodelling (Figure 5)48. 
 
igure 5. The wound-healing cascade of an acute trauma. The progression of acute 
 
F
wound healing from hemostasis to the final phases of matrix remodelling is dependent 
on a complex interplay of varied acute wound-healing events. Cytokines play a central 
role in wound healing and serve as a central signal for various cell types and healing 
events. Taken from Monaco et al. (2003)48. 
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Hemostasis 
nt trauma create a vascular injury and thereby initiate the molecular and All significa
cellular responses that establish hemostasis. The healing process cannot proceed until 
hemostasis is accomplished. Primary contributors to hemostasis include 
vasoconstriction, platelet aggregation, and fibrin deposition resulting from the 
coagulation cascades. Vasoconstriction is initiated by the release of vasoactive amines, 
which occurs when the dermis is penetrated. Epinephrine is released into the peripheral 
circulation, whereas stimulation of the sympathetic nervous system results in local 
norepinephrine release. Injured cells secrete prostaglandins, such as thromboxane, that 
contribute further to vasoconstriction. In wound healing, platelets are the first cells to 
arrive at the site of injury. Mediated by the integrin αIIbβ3, adult platelets adhere to 
wound connective tissue. They are activated by contact with exposed collagen and 
collagen fragments to discharge their alpha granules and aggregate to form a platelet 
plug. Adhesion proteins (such as fibrinogen, fibronectin, thrombospondin, and von 
Willebrand factor) and growth factors (such as platelet-derived growth factor [PDGF] 
and transforming growth factor-β [TGF-β]) are released from the alpha granules and 
promote further platelet adhesion and aggregation. The end product of the hemostatic 
process is clot formation. Clots are primarily composed of a fibrin mesh containing 
aggregated platelets and blood cells. The coagulation cascades are composed of intrinsic 
and extrinsic components that are individually triggered (Figure 6)49. The intrinsic 
coagulation cascade is initiated by activation of factor XII (FXII), which occurs when 
blood is exposed to foreign surfaces. The release of tissue thromboplastin factor (TF) 
from damaged tissue initiates the extrinsic coagulation pathway. Tissue thromboplastin 
factor binds and activates coagulation factor VII (FVII). The TF-FVIIa complex 
subsequently acts as a potent activator of coagulation factor IX (FIX) and factor X (FX) 
in the presence of calcium (Ca2+), resulting in the formation of FIXa and FXa.  
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igure 6. Schematic overview of the blood coagulation cascade. The model is divided 
Spronk et al. (2003)50. 
 
 
F
into the intrinsic (left side) and extrinsic (right side) pathway. The blood coagulation 
factors are denoted in Roman numbers. Active forms are denoted by a small ‘a’ added 
to the Roman number. TF, tissue factor; PL, phospholipid; HMWK, high molecular 
weight kininogen. Positive feedback loops by thrombin (dotted lines), FIXa (dashed-
dotted line), and FXa (dashed line) are indicated in grey. Y indicates inhibition by 
activated protein C (APC) and tissue factor pathway inhibitor (TFPI). Adapted from 
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Activation of both the extrinsic and the intrinsic pathways of coagulation leads to 
formation of FIXa which, in the presence of phospholipids, calcium, and activated 
 
Figure 7. brin showing the major structural 
domains and some cellular binding interactions. Adapted from Mosesson et al. (2001)51. 
coagulation factor VIII (FVIIIa), is a potent activator of FX. Once formed, FXa converts 
prothrombin into thrombin. This reaction is dependent on the formation of the 
prothrombinase complex that consists of FXa, activated coagulation factor V (FVa), and 
phospholipids, and requires calcium as cofactor. Active thrombin converts fibrinogen 
into fibrin, resulting in propagated clot formation and leading to repair of the tissue 
injury. Another important function of thrombin is the activation of coagulation factor 
XIII (FXIII) to FXIIIa. This enzyme stabilizes, in the presence of calcium, the fibrin 
clot via covalent cross-links49. Fibrinogen molecules are elongated 45-nm structures 
consisting of two outer D domains, each connected by a coiled-coil segment to a central 
E domain (Figure 7). They are comprised of two sets of three polypeptide chains termed 
α, β, and γ which are joined together within their N terminal E domains by disulfide 
bridges. The thrombin-induced conversion of fibrinogen into fibrin is a complex process 
(simplified in Figure 7). The N-terminal region of each α chain contains a fibrinopeptide 
A (FPA) sequence, cleavage of which by thrombin initiates the fibrin assembly process 
by exposing the polymerization E site. Each E site combines with a constitutive 
complementary binding pocket in the D domain of neighbouring molecules. 
Schematic diagram of fibrinogen and fi
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These initial E:D associations cause fibrin molecules to align into a staggered 
overlapping end-to middle domain arrangement forming double-stranded twisting fibrils 
(Figure 8). Fibrils also undergo lateral associations to form larger diameter fibrils and 
the fibers constitute the three-dimensional fiber network. Two types of branch junctions 
occur in fibrin network structures. The first type occurs when a double-stranded fibril 
converges laterally with another fibril to form a four-stranded fibril, a so-called 
‘bilateral’ junction. Lateral convergence of larger fibrils or fibers evidently result in 
larger versions of this type of branch junction. The second type of branch junction, 
termed ‘equilateral’, forms by the coalescence of three fibrin molecules that connect 
three fibrils of equal widths (Figure 8). Equilateral junctions form with greater 
frequency when fibrinopeptide cleavage is relatively slow. Under such conditions the 
networks are more branched and the matrix ‘tighter’ (i.e. less porous) than those formed 
at high levels of thrombin. Network density is dependent on the amount of thrombin, 
calcium, and activated coagulation factor XIII (FXIIIa)51. Fibrin forms the network that 
stabilizes the platelet plug and therefore becomes a key component of the provisional 
matrix that develops in the wound soon after the injury. Fibrin networks contain 
vitronectin derived from serum and aggregating platelets. This action facilitates the 
binding of fibronectins, which are produced by fibroblasts and epithelial cells. 
Fibronectin is the second key component of the early provisional wound matrix. The 
fibronectin molecule has nearly a dozen binding sites for cellular attachment. These 
attachment sites are essential for cellular migration along the matrix. The fibrin-
fibronectin matrix also traps circulating cytokines for the use in the following stages of 
wound healing. 
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igure 8. Schematic diagram of fibrin assembly and crosslinking. Assembly of fibrin 
egins with non-covalent interactions (D:E) between the E and D sites (dotted lines) to 
rm end-to-middle staggered overlapping double-stranded fibrils (upper part of the 
 
F
b
fo
sketch). Fibrils also branch and undergo lateral associations to form larger diameter 
fibrils and fibers. [Insert: critical point dried thin fibril matrix containing equilateral 
(arrows) and bilateral (arrowheads) branched junctions; bar, 100 nm]. Adapted from 
Mosesson et al. (2001)51. 
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Inflammation 
One of the primary functions of inflammation is to bring inflammatory cells into the 
jured area. These cells destroy bacteria and eliminate debris from necrotic and 
poptotic cells and damaged matrix so that the repair processes can proceed. Migrating 
sform into macrophages as they migrate into the extravascular space in a 
pany the healing 
rogresses. Cytokine networks continue to be part of the following healing processes as 
lasia, epithelialization, and angiogenesis. Although 
in
a
monocytes tran
process that is stimulated by chemotactic factors such as collagen fragments, fibronectin 
and elastin derived from the damaged matrix, TGF-β, complement components, 
enzymatically active thrombin, and serum proteins. All leukocytes require activation 
before they can perform their vital functions in the wound environment. Interleukin-2 
(IL-2) and interferon-σ (INF-σ) derived from T lymphocytes are involved in 
macrophage activation. In addition to phagocytosing debris, macrophages also 
contribute to matrix breakdown by releasing matrix metalloproteinases (MMPs) such as 
collagenases and elastase into the wounded area. These multipurpose cells are involved 
in many aspects of healing through the cytokines and immunomodulatory factors they 
produce. Macrophage-produced cytokines are involved in angiogenesis, fibroblast 
migration and proliferation, collagen production, and possibly wound contraction. TGF-
β, fibroblast growth factor-2 (FGF-2), insulin-like growth factor-1 (IGF-1), PDGF, and 
IL-1 are several of the most crucial macrophage-derived cytokines.  
 
Cellular migration and proliferation 
The initial fibrin-fibronectin matrix is heavily populated by inflammatory cells, whereas 
fibroblasts and endothelial cells will predominate and accom
p
cytokine release contributes to fibrop
much is known about the signals that stimulate the predominant activities during this 
phase of healing, less is known about the signals that bring these activities to a 
controlled end. Negative feedback mechanisms that deactivate cells after they have 
completed their tasks are also essential for normal wound healing. Moreover, fibroblasts 
are required in the healing wound, since native fibroblasts were lost or damaged in the 
injury. Repopulation of the wounded area with fibroblasts occurs as a result of 
fibroblast migration from adjacent tissues and proliferation of cells in the wound. In 
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addition, undifferentiated cells in the environment of the wound may transform into 
fibroblasts under the influence of cytokines in the wound milieu. Factors that stimulate 
fibroblast migration include TGF-β, epidermal growth factor (EGF), PDGF, and 
fibronectin. Upregulation of cell membrane integrin receptors that bind to fibrin and 
fibronectin in the provisional wound matrix is required for fibroblasts to migrate. An 
integrin molecule is composed of two noncovalently associated transmembrane 
glycoprotein subunits called α and β (Figure 9).  
 
 
 
Figure 9.  cell-surface matrix receptor. The α and β 
α subunit is made initially as a 
ngle polypeptide chain, which is then cleaved into one small transmembrane domain 
nd one large extracellular domain that contains divalent-cation-binding sites; the two 
The subunit structure of an integrin
subunits are held together by noncovalent bonds. The 
si
a
domains remain held together by a disulfide bound. The extracellular part of the β 
subunit contains a single divalent-cation-binding site, as well as a repeating cystein-rich 
region, where intrachain disulfide binding occurs. Taken from Alberts et al. (2002)52.  
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The binding of integrins to their ligands depends on extracellular divalent cations (Ca2+ 
or Mg2+, depending on the integrin), reflecting the presence of divalent-cation-binding 
omains in the extracellular part of the α and β subunits. The type of divalent cation can 
fluence both the affinity and the specificity of the binding of an integrin to its ligands. 
es including MMP-1, 
d
in
Most integrins are connected to bundles of actin filaments. After the binding of a typical 
integrin to its ligand in the matrix, the cytoplasmic tail of the β subunit binds to several 
intracellular anchor proteins, including α-actinin, talin, and filamin. These anchor 
proteins can bind directly to actin or to other anchorn proteins such as vinculin, thereby 
linking the integrin to actin filaments in the cell cortex52. Integrin expression is, 
therefore, vital to the migration of fibroblasts and other cell types. 
The orientation of fibers in the matrix also influences cellular migration, in that cells 
tend to migrate along fibers and not across them. The ability of fibroblasts to migrate 
may be impeded by residual debris in the wound environment. To facilitate migration 
through such debris, fibroblasts secrete several proteolytic enzym
gelatinase (MMP-2), and stromelysin (MMP-3). TGF-β stimulates fibroblasts to secrete 
these enzymes. The MMPs constitute a multigene family of over 25 secreted and cell 
surface associated or transmembrane enzymes. All MMPs are produced as zymogens 
containing a secretory signal sequence and a propeptide whose proteolytic cleavage is 
required for MMP activation. The propeptide is followed by the catalytic domain that 
contains the zinc binding motif. At least two MMPs (MMP-7 and MMP-26) are 
composed only of the signal peptide, propeptide, and catalytic domain, and are known 
as minimal domain MMPs (Figure 10). Most of the remaining MMPs contain a 
haemopexin-like domain that is thought to confer some degree of substrate specificity, 
and several have additional features, such as serine protease recognition motifs or 
fibronectin-like repeats (Figure 10). Finally, a subclass of MMPs contains a 
transmembrane and intracellular domain and are often referred to as MT-MMPs53. 
MMPs targets include other proteinases, proteinase inhibitors, chemotactic molecules, 
clotting factors, latent growth factors, growth factor-binding proteins, cell surface 
receptors, cell-cell adhesion molecules, and almost all structural extracellular matrix 
proteins. Thus MMPs are able to regulate many biologic processes and their activity is 
firmly regulated. MMPs are regulated at the transcriptional and post-transcriptional 
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levels and are also controlled at the protein level via their activators, their inhibitors, and 
their cell surface localization54.  
 
 
 
Figure 10. Protein structure of MMPs. The principal structural subclasses of MMPs are 
shown and the different domains indicated. Individual MMPs that belong to each 
structural subclass are listed. Taken from Stamenkovic (2003)53. 
pillaries at the wound 
eriphery. These sprouts grow through cellular migration and proliferation. Endothelial 
ells migrate during angiogenesis by forming transient contacts between their cells 
sed integrins to the provisional fibrin-fibronectin matrix in a similar 
 
 
Angiogenesis 
During angiogenesis, endothelial sprouts derive from intact ca
p
c
surface expres
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manner as fibroblasts do. Upregulation of αvβ3 integrins is specifically associated with 
angiogenesis. Endothelial cell migration is also facilitated by the cell’s ability to 
produce MMPs that break down collagen, fibronectin, laminins, elastin, and other 
extracellular matrix molecules. These breakdown products induce further induction of 
wound healing and tissue regeneration process. In addition, matrix degeneration permits 
endothelial cells movement and process formation. Angiogenesis process is regulated 
by a variety of growth factors and cytokines. The two most important growth factors 
that contribute to angiogenesis are vascular endothelial growth factors (VEGFs) and 
FGF-2. FGF-2 has a strong mitogenic effect on endothelial cells and promote 
endothelial cell proliferation and differentiation. They promote endothelial cell 
migration during the early phase of the wound repair through upregulation of the 
urokinase-type plasminogen activtor55, which leads to clot formation and fibrin 
deposition, and facilitates the migration of endothelial cells through the fibrin clot. 
During granulation tissue formation, FGF-2 also promotes endothelial cell migration by 
induction of endothelial cell-surface αVβ3 integrin expression, which mediates the 
binding of endothelial cells to the extracellular matrix. VEGF is a potent mitogen for 
human microvascular endothelial cells and induces endothelial cell migration and 
sprouting by up-regulation of several endothelial integrin receptors including, α1β1, 
α2β1, and αVβ3. VEGF acts as a survival factor for endothelial cells through induction of 
the expression of the anti-apoptotic protein Bcl-256. This pro-survival activity of VEGF 
requires the phosphatidylinositol 3 (PI3)-kinase/Akt signal transduction pathway57. 
 
Re-epithelialization 
The processes of cellular migration and proliferation occur under the control of various 
growth factors including EGF, platelet-derived EGF, keratinocyte growth factor (KGF), 
nd TGF-α. Some are produced by inflammatory cells and others are derived from the 
selves. Epithelial cell migration requires the development of actin 
a
epithelial cells them
filaments within the cytoplasm of migratory cells and the disappearance of desmosomes 
and hemidesmosomes that link them to each other and to the basement membrane, 
respectively. At least some of these processes are dependent on changes in the integrin 
expression pattern on the cell membranes. For different integrins it has been shown that 
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they are up-regulated as soon as a certain stimulus occurs (e.g. VEGF-A165 and VEGF-
R2). If the epidermal basement membrane is intact, cells simply migrate over it. In 
wounds in which it has been destroyed, the cells initially begin to migrate over and into 
the fibrin-fibronectin provisional matrix. As they migrate across the matrix, however, 
epithelial cells regenerate a new basement membrane. Re-establishment of a basement 
membrane under migrating cells involves the secretion of vitronectin, tenasin, and type 
I and V collagens. When epithelial cells reach each other from peripheral growth 
towards the middle of the wound they become contact inhibited and hemidesmosomes 
re-form between the cells and the basement membrane, and vitronectin and tenasin 
secretion decreases. A new functional basement membrane is formed and provides 
epithelial support as well as protection against the other milieu.  
 
Protein synthesis and wound contraction 
Collagen constitutes more than 50 % of the protein in scar tissue, and its production is 
essential to the healing process. Fibroblasts are responsible for the synthesis of collagen 
nd other proteins synthesized during the repair process. The concentration of collagen 
ype I collagen predominates and forms 80 % 
a
subtypes varies among different tissues. T
to 90 % of the collagen found in the intact dermis. The remaining 10 % to 20 % is type 
III collagen. In contrast, granulation tissue that forms soon after the injury contains 30 
% type III collagen. Accelerated type III collagen synthesis is correlated with 
fibronectin secretion after the injury. Type II collagen is found almost exclusively in 
cartilage, whereas type IV collagen is found in all basement membranes. Type V 
collagen is found in blood vessels, whereas type VII collagen forms the anchoring 
fibrils of epidermal basement membrane. Proteoglycans are also matrix components that 
are synthesized by fibroblasts after the injury. Their concentration in injured tissues 
gradually increases with time in a manner paralleling collagen synthesis. Proteoglycans 
consist of a protein core covalently linked to one or more glycosaminoglycans. 
Proteoglycans bind proteins and change their orientation in a manner that influences 
their activity. Dermatan sulfate is a proteoglycan that orients collagen molecules in a 
manner that facilitates fibril formation. Wound contraction is characterized by a 
predominance of myofibroblasts at the wound periphery. Although Gabbiani et al58 
General introduction  31  
postulated that these cells were the ‘motor’ that contracted a wound. More recent work 
with collagen lattices has suggested that fibroblasts in the central part of the wound may 
be more important to the contraction process48. It is clear, however, that the process of 
wound contraction is cell mediated and does not require collagen synthesis. TGF-β and 
possibly other cytokines are involved in the wound contraction process59. 
 
Remodelling of the wound matrix 
The nature of the wound matrix changes with scar tissue remodelling. Immature scar 
tissue contains a disorganized array of fine collagen fibers, which is gradually replaced 
y thicker fibers arranged in a parallel manner. In addition, the number of cross-links 
s gradually increases therefore slowly increasing the 
ensional 
ltrastructure. These proteins provide many functions including support and tensile 
ve as a reservoir for 
b
both within and between molecule
mechanical stability. As the nature of the collagen matrix changes, it becomes less 
cellular through apoptosis of cells involved in the healing process. The rate of collagen 
synthesis decrease and reaches an equilibrium with the rate of collagen breakdown. The 
downregulation of collagen synthesis is mediated by TNF-α60, γ-interferon61, and the 
collagen matrix itself62. MMPs are closely involved with the breakdown of collagen 
molecules that occurs actively during the remodelling process. Although scar tissue 
remodelling does not seem to be as complex as other aspects of the healing process, it is 
essential to the formation of a stable wound coverage leading to the formation of the 
mature scar tissue and rearrangement for tissue regeneration. Moreover, the remodelling 
process is associated with a substantial increase in wound-breaking strength48. 
 
The extracellular matrix as a scaffold for tissue reconstruction  
The extracellular matrix is a complex mixture of structural and functional proteins, 
glycoproteins, and proteoglycans arranged in a unique, tissue specific three-dim
u
strength, attachment sites for integrin cell surface receptors, and ser
signalling molecules and growth factors that modulate such diverse processes as cell 
migration, cell proliferation and orientation, angiogenesis and vasculogenesis, 
inflammation, immune responsiveness and wound healing. Stated differently, the ECM 
is a essential and dynamic component of all tissues and organs and is nature’s natural 
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scaffold for tissue and organ morphogenesis, maintenance, and reconstruction following 
an injury. 
Scaffolds for tissue reconstruction and replacement must have both appropriate 
structural and functional properties. However, the difference between structural and 
functional characteristics of the protein scaffolds is becoming increasingly blurred. 
Domains of proteins originally thought to have purely structural properties have been 
identified and found to have significant and highly modulating effects on cellular 
behaviour. For example, the RGD (arginine-glycine-aspartic acid) peptide that promotes 
adhesion of numerous cell types was first identified in the 10th fibronectin type III 
domain of fibronectin; a molecule originally described for its structural properties. 
Several other peptides have since been identified as ‘dual function’ proteins including 
types I and VI collagen, laminins, entactin, fibrinogen, and vitronectin. If one considers 
the ECM to be a degradable bioscaffold usable for implantation, both the structural and 
the functional components are transient due to the rapid rate of degradation of ECM 
scaffolds in vivo. Collagen is the most abundant protein within the ECM. More that 20 
distinct types of collagen have been identified. The primary structural collagen in 
mammalian tissues is type I collagen. Collagen has maintained a highly conserved 
amino acid sequence through the course of evolution. For this reason allogeneic and 
xenogeneic sources of type I collagen have been long recognized as a useful scaffold for 
tissue repair with low antigenic potential. Collagen types other than type I exist in 
naturally occurring ECM, although in much lower quantities. Another example is type 
IV collagen being present within the basement membrane of all vascular structures. It is 
an important ligand for endothelial cells. Type VII collagen is an important component 
of the anchoring fibrils of keratinocytes to the underlying basement membrane of the 
epidermis. Type VI collagen functions as a ‘connection’ of functional proteins and 
glycosaminoglycans to larger structural proteins such as type I collagen, helping to 
provide a gel like consistency to the ECM. Type III collagen exists within selected 
submucosal ECMs, such as the submucosal ECM of the urinary bladder, where less 
rigid structures are required for its appropriate function. This diversity of collagens 
within a single scaffold material is partially responsible for the distinctive biologic 
activity of ECM scaffolds and is exemplary of the difficulty in designing such a 
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composite in vitro. In summary, the ECM is a rich source of numerous types of collagen 
and the relative concentrations and orientation of these collagens to each other provide 
an environment for cell growth both in vitro and in vivo. 
Fibronectin, one of the ‘dual function’ proteins mentioned earlier, represents an 
important component of the ECM. Fibronectin is the second frequent molecule within 
the ECM. Fibronectin exists both in soluble and tissue isoforms and possesses many 
desirable properties of a tissue repair scaffold including ligands for adhesion of many 
e repair is one of the 
nd of many growth factors (e.g. FGF family, VEGF) make the heparin-rich 
pecific biological 
cell types. Fibronectin exists in two-dimensional ECMs such as basement membranes as 
well as in three-dimensional ECMs such as submucosal structures. 
Laminins are a family of complex adhesion proteins found in the ECM; especially 
within basement membrane ECMs. The prominent role of laminins in the formation and 
maintenance of vascular structures is especially noteworthy when considering the ECM 
as a scaffold for tissue repair. Vascularization of scaffolds for tissu
rate limiting steps in the field of tissue engineering and proteins such as laminins are 
receiving much attention as an important component of endothelial cell friendly scaffold 
materials. 
Glycosaminoglycans (GAGs) are important components of ECM and play important 
roles in binding of growth factors and cytokines, water retention, and maintaining the 
gel properties of the ECM. The heparin binding properties of numerous cell surface 
receptors a
GAGs extremely desirable components of scaffolds for tissue repair.  
Although cytokines and growth factors are present within the ECM in small quantities, 
they act as potent modulators of cell behaviour. The list of growth factors is extensive 
and includes EGF, TGF-β, VEGFs, KGF, PDGF, and hepatocyte growth factor (HGF). 
These factors tend to exist in multiple isoforms, each with its s
activity. Purified forms of growth factors and biologic peptides have been investigated 
in recent years as therapeutic tools to encourage blood vessel formation (VEGF), 
inhibiting blood vessel formation (angiostatin), stimulating deposition of granulation 
tissue (PDGF), and encouraging epithelialization of wounds (KGF). However, these 
therapeutic approaches have struggled with determination of optimal dose, localized and 
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sustained release at the desired site, and the inability to turn the factors ‘on’ and ‘off’ as 
needed during the course of tissue repair63.  
 
 
Cell-ECM interactions 
For tissue engineering strategies it is essential to know how cells can interact with the 
CM and transmit the information received by the extracellular molecules into an 
ll-matrix contacts have several major purposes: to anchor 
E
intracellular event. Ce
elements of the ECM to the cell surface; to form a continuous physical linkage between 
ECM and elements of the cytoskeleton that is required for cell adhesion and movement; 
to act as localised sites for transmission of mechanical force and elastic recoil between 
cells and ECM, and to act as sites for localised activity of signalling molecules. They 
are thus essential components in the integration and organisation of cellular and 
acellular elements within tissues. The principal structural elements of a cell-matrix 
contact are shown in Figure 11. On the extracellular face, matrix macromolecules bind 
to specific adhesion receptors, such as integrins, which are typically transmembrane or 
glycosylphosphatidylinositol-linked glycoproteins (see also Figure 9). On the 
intracellular side of the plasma membrane, the cytoplasmic domains of receptor 
molecules interact with either (i) cytoplasmic proteins which provide linkage to 
cytoskeletal filaments, or (ii) larger sets of cytoplasmic proteins which cluster by 
protein-protein interactions to form submembranous junctional complexes which then 
interface with cytoskeletal filaments64. The formation of molecular clusters at the cell 
surface lead to a direct or indirect control of cellular activities such as adhesion, 
differentiation, migration, proliferation and apoptosis, and are therefore essential in 
processes such as healing of tissue injuries or the progression of human cancer.  
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Figure 11. Schematic representation of the general structure of cell-to-matrix contacts. 
Not to scale. Taken from Adams (2001)64. 
 
 
Mechanotransduction at cell-matrix and cell-cell contacts 
Cell-matrix adhesions depend on the differentiation state of cells, their physical location 
and the local forces sensed by the cells. One of the main challenges to understand cell-
matrix adhesions is the enormous diversity and complexity of the in vivo 
microenvironments that cells encounter65. Recent studies have shown that many distinct 
types of adhesions exist between cells and the ECM; these adhesions differ in size, 
shape, and biochemical composition and probably differ in function as well66. Because 
these adhesions continually remodel in response to changes in the composition, 
architecture, and mechanical properties of the cell-matrix interface, they appear to be a 
central mechanism by which cells can change behaviour in response to structural and 
mechanical cues. The largest and most stable types of contacts include focal contacts or 
adhesion plaques, focal adhesions, fibrilar adhesions and hemidesmosomes. Other 
contact which are smaller, transient, or restricted distributed include filopodia, spikes, 
lamellae, podosomes and pseudopodia64. The best-characterized and largest of these 
structures is the focal adhesion (FA). FA complexes contain specific integrins (e.g. α5β1 
binding to fibronectin and αvβ3 linking to vitronectin)  and a number of cytoskeleton-
General introduction  36  
associated proteins, such as talin, vinculin, α-actinin, filamin, and focal adhesion kinase, 
that connect the cytoplasmic tails of integrins with F-actin. These molecules form a 
physical bridge that spans from the ECM to the cytoskeleton. It is now generally 
accepted that mechanical forces can be transmitted across the membrane through 
integrins that mediate cell-ECM adhesion. For example, mechanical stresses applied via 
integrins resulted in coordinated changes in the cytoskeleton and the nuclear shape, 
indicating a long-range direct force-transmitting pathway from the cell surface into the 
nucleus67. Thus cell-matrix adhesions not only play a physical role in organizing cells 
into tissues but also provide an important biochemical role in the regulation of many 
cellular processes. Many signalling proteins (e.g., src, FAK, Ras) localize within cell-
matrix adhesions. Because these signalling proteins function in cascades initiated by 
growth factors, their concentration at adhesions suggests that adhesions may act to 
coordinate integrin and growth factor signalling. Specific integrins within these 
adhesions appear to interact with specific growth factor receptors, these adhesions may 
enable cells to generate unique responses when exposed to particular combinations of 
ECM and growth factors. For example, signalling through basic fibroblast growth factor 
receptor in endothelial cells requires ligation of the integrin αvβ3, whereas signalling 
through vascular endothelial growth factor receptor uses αvβ5; because αvβ3 and αvβ5 
bind to different classes of ECM proteins, the response of endothelial cells to a given 
growth factor depends on its underlying ECM. Thus adhesions provide a physical 
structure that allows many important biochemical signals to initiate fundamental 
changes in cell behaviour. Cell-cell adhesions, similar to cell-matrix adhesions, are 
emerging as important players in mechanotransduction. Distinct types of cell-cell 
adhesions include adherens junctions (AJs), tight junctions, and gap junctions, which 
are mediated by cadherins, occludins, and connexins, respectively. In some cases, 
especially with blood-borne cells, intercellular adhesions may be mediated by integrins. 
Among these different cell-cell adhesions, the AJ is perhaps one of the most important 
for transmitting mechanical signals directly to the actin cytoskeleton. The homotypic 
engagement of cadherins, a family of transmembrane Ca2+-dependent adhesion 
molecules, initiates the formation of AJs and recruits scaffolding proteins that anchor 
the actin cytoskeleton. FAs and AJs exhibit many remarkable similarities. First, both 
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comprise of dense clusters of transmembrane receptors that attach the cell to the 
external environment. Second, both provide a highly dynamic and responsive 
mechanical link to the actin cytoskeleton. Third, the architecture of both FAs and AJ 
comprise of a large number of structural and signalling molecules that cluster at the 
junction through multiple, redundant protein-protein interactions. Several of these 
components, including α-actinin, vinculin, zyxin, moesin, and Arp2/3, are shared by 
both types of adhesions68. 
 
This work, set in the field of experimental tissue engineering, is motivated by the 
desperate request for a practical treatment to seal/heal PPROM. Presently, the 
therapeutic options to close a wound in premature ruptured fetal membranes are 
extremely limited. It is fair to say that there is no treatment of PPROM. The worthwhile 
consequence of an effective treatment of the ruptured fetal membranes could be to save 
the life and health of a baby and its mother. A particular challenge in our approach to 
treatment of PPROM is given to design a tissue engineered construct that can be 
delivered to the site of membrane rupture by minimal invasive methodology, namely 
fetoscopic methods. Our approach derived from the hypothesis that an amnion cell-
matrix construct could permit an immediate closure of the amnion, therefore stopping 
the fluid leakage and promoting the wound closure in the fetal membranes. An 
additional aspect was to determine whether amnion cells derived from different 
gestational ages bear an inherent potential to proliferate, migrate and potentially heal a 
given injury. 
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Scope of the thesis 
 
The aim of this thesis was to develop a tentative option for the treatment of preterm 
premature rupture of the membranes (PPROM) patients based on tissue engineering. 
The idea was to develop a cell-matrix system consisting of extracellular matrices 
colonized with human amnion epithelial and mesenchymal cells. Such cell-matrix 
systems may be precisely administered to the rupture site via endoscopical methods. In 
the recent years tissue engineering therapeutics approaches have become an important 
medical option after injury in many aspects of modern medicine. 
 
Three major aims were formulated: 
 
First: human amnion cell isolates were generated as a cellular source for the 
reconstruction of a tissue engineered amnion membrane after PPROM, and the 
establishment of conditions for their expansion in vitro were characterized (Chapter 2). 
The proliferation potential of cultured human amnion epithelial and mesenchymal cells 
from preterm and term placenta was investigated under various cell growth conditions. 
 
Secondly: the repair potential of human amnion cells from preterm and term placenta 
was examined and compared (Chapter 3). Repair potential and effect of potential 
proliferation stimulants were investigated using an in vitro lesion repair assay. 
 
Finally: the most critical and challenging part of this project involved the design of a 
cell containing matrix that mimics the architecture of the native amnion, described in 
Chapter 4. The behaviour of human amnion cells in three-dimensional (3D) collagen I 
and fibrin matrices was investigated. The envisioned aim was to develop a defined cell-
containing piece of matrix that can potentially be used to seal/heal the amnion 
membrane after PPROM in vivo. 
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Chapter 2 
 
 
 
Inducing proliferation of human amnion 
epithelial and mesenchymal cells for 
prospective engineering of membrane repair 
 
 
 
Published in:  J Perinat Med 2003;31:287-94. 
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Abstract 
 
Objective: To prepare a tissue engineering approach to fetal membrane repair after 
premature rupture of the membranes (PROM) by characterizing the proliferation 
potential of human amnion epithelial and mesenchymal cells from preterm and term 
placenta in primary culture. 
Methods: Amnion epithelial and mesenchymal cells from 15 preterm (23-36 week) and 
27 term placentas collected at cesarean section were separated enzymatically, 
characterized immunohistochemically (anti-cytokeratin-18 and anti-E-cadherin, and 
anti-vimentin, respectively), and their ratio determined. Proliferation on tissue culture 
polystyrene (TCPS) or collagen in one medium and on TCPS in four different media 
after 14 days was measured photometrically and compared in preterm vs. term placenta. 
For statistical analysis the Mann-Whitney test was used. 
Results: Preterm and term epithelial : mesenchymal cell ratios were 4.3:1 and 7.8:1. 
Term epithelial cells proliferated similarly on TCPS or collagen. Mesenchymal cells 
proliferated only with fetal bovine serum (FBS). Proliferation of term amnion cells in 
medium containing FBS, epithelial growth factor (EGF), insulin, transferrin and 
triidothyronine (T3) was significantly increased (p<0.001) compared with the other 
three media, and percentage proliferation was slightly higher in preterm cells. 
Conclusion: Characterization of human amnion epithelial and mesenchymal cells 
identified the most potent proliferation-inducing medium yet. Studies of the wound-
healing potential of these cells are needed, examining their behavior and proliferation 
on fibrin microbeads and other extracellular matrixes as the next step towards 
engineering membrane repair in PROM. 
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Introduction 
Spontaneous premature rupture of membranes (PROM) complicates about 1 % of all 
pregnancies and is the leading cause of perinatal morbidity and mortality69, 70, especially 
in the previable period70. Iatrogenic PROM is a major limitation of uterine endoscopy; 
the incidence is 10 % after laser coagulation for twin-twin transfusion syndrome17, >30 
% after fetoscopic cord ligation18, and >62 % after endoscopic tracheal clipping19. Most 
research has concentrated on the pathogenesis of PROM71, 72 while largely neglecting 
the repair and healing potential of fetal membrane. The association of changes in the 
secretion of matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors 
(TIMPs) with the restoration of fetal membrane integrity in an animal model following 
fetoscopy suggests an active repair process73. Clinical experience also supports the 
hypothesis of fetal membrane repair given the very low incidence of PROM after 
routine midtrimester amniocentesis74, 75 and the spontaneous ‘resealing’ reported in 7.7 
% to 9.7 % cases of PROM24, 76. 
Several treatments for PROM have been described, from collagen plugs in a rabbit 
model41 to amniopatch30, amniograft46, maternal blood clot patch29 and fibrin glue77 in 
humans. However, cell-based or tissue-engineered therapies, e.g. using cartilage78, 
endothelium79 or skin80, have since become an alternative and promising option after 
injury in many branches of medicine. To develop a new approach to restoring the fetal 
membrane integrity after PROM, we therefore wished to characterize and compare the 
proliferation potential of cultured human amnion epithelial and mesenchymal cells from 
preterm and term placenta under a variety of growth factor conditions. 
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Material and methods 
 
Primary human amniotic cell cultures  
15 preterm (23-36 week) and 27 term (37-41 week) placentas with attached membranes 
from women without PROM, signs of infection or fetal chromosomal abnormalities 
were collected immediately after elective cesarean section. Amnion and chorion laeve 
tissues were separated by blunt dissection81, the amnion was cut approximately 2 cm 
from the placental disc to avoid the ‘zone of extreme altered morphology’82 and then 
washed in phosphate buffered saline (PBS; Sigma-Aldrich, Switzerland) to remove 
cellular debris and blood. Amnion epithelial and mesenchymal cells were separated by 
differential enzymatic dissociation6 and their ratio determined. Cell viability assessed by 
trypan blue dye exclusion was 97 %. After plating at a density of 5000 per 50 μl 
medium per well (96-well MicroWell® plates, Nunc Nunclon), the cells were 
maintained in culture in a humidified atmosphere at 37° C and 5 % CO2 with medium 
replacement after 48 or 72 h. 
 
Cell characterization by immunohistochemistry 
The cells were characterized using antibodies specific for two separate filament proteins 
expressed in epithelial and mesenchymal cells, respectively. The epithelial cell line 
marker, cytokeratin-18, was detected by a monoclonal antibody (Sigma-Aldrich, 
Switzerland) at 1:1000 dilution. The mesenchymal cell line marker, vimentin, was 
detected by a monoclonal antibody (Sigma-Aldrich, Switzerland) at 1:100 dilution. 
Epithelial cells were also identified using, at 20 μg/ml, a monoclonal antibody (R&D 
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Systems, Europe) which detects E-cadherin83, the cell adhesion molecule specific to 
human epithelium. 
Antibodies were diluted in 2 % bovine serum albumin (BSA) in PBS. Secondary 
antibodies were conjugated to tetramethylrhodamine isothiocyanate (TRITC; Sigma-
Aldrich, Switzerland) or fluorescein isothiocyanate (FITC; Sigma-Aldrich, 
Switzerland). Anti-mouse IgG labelled with TRITC was used at 1:200 dilution and anti-
goat IgG labeled with FITC at 1:400 dilution. 
Cells were fixed and permeabilized with ethanol (-20° C) before being rinsed with PBS. 
They were then incubated with 2 % BSA in PBS to block nonspecific binding. Primary 
antibodies were applied and the cells incubated at room temperature for 1 h, then 
washed three times with PBS and incubated in the dark with second antibody at room 
temperature for 1 h. After the final PBS wash, they were analyzed by fluorescence 
microscopy (Carl Zeiss) at ×20. Control cells were treated identically without the 
primary antibodies. Cell images (CCD camera, Hamamatsu) were processed using 
QWin software (Leica Microsystems) and Photoshop version 5.0. 
 
Cell proliferation assay 
Cell cultures were tested after 1, 3, 7 and 14 days of culture using the proliferation 
reagent WST-1 (Roche, Switzerland). The assay is based on the reduction of WST-1 to 
water-soluble formazan by viable cells84. After incubating the cells with WST-1 for 2 h, 
formation of the formazan dye in the microtiterplate was quantitated with an ELISA 
plate reader at 450 nm. Absorbance correlated directly with the number of viable cells. 
Experiments were done in duplicate and the means used for analysis. 
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Variation of culture conditions, gestational age and media 
We varied the following factors in our proliferation parameter test system (Figure 1): 
• culture conditions: cells from term placenta (n=5) were cultured on tissue culture 
polystyrene (TCPS) and collagen I (Sigma-Aldrich, Switzerland) using a serum-free 
medium (medium 1: Ham's F12:DMEM + 50 ng/ml EGF, 2.5 μg/ml insulin, 5 μg/ml 
transferrin, and 0.1 ng/ml T3) shown to be optimal for human amnion epithelial cells85 
and containing known factors at precise concentrations. 
• gestational age (GA): cells from preterm placenta (n=3) were cultured on either TCPS 
or collagen I using the same serum-free medium. 
• media: cells from preterm (n=4) and term (n=18) placenta were tested in three other 
media (medium 2 = medium 1 + 50 ng/ml EGF; medium 3 = medium1 + 10 % FBS; 
medium 4 = Ham’s F-12:DMEM (1:1) + 10 % FBS). 
After 14 days we compared percentage proliferation between preterm and term cultures, 
defining proliferation as a fourfold increase over baseline (D1) absorbance (WST-1); 
this was on the basis of an amnion cell doubling time of 150-210 h, which translates 
into an approximate fourfold increase in cell count after 14 days86. Our hypothesis, 
based on the known increase in apoptosis with GA87, was that preterm cultures would 
show the higher proliferation potential. 
 
 
Statistical analysis 
Results were presented as the mean ± SD. For calculation of significance (p<0.05) the 
Mann-Whitney test was used. 
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Figure 1. Study flowchart. 
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Results 
 
Epithelial:mesenchymal cell ratios 
The yield of amnion epithelial cells was approximately 2 million/g of amnion tissue. 
Epithelial : mesenchymal cell ratios, plotted vs. GA in Figure 2, were 4.3:1 and 7.8:1 in 
preterm and term placenta, respectively. 
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Figure 2. Amnion epithelial (n) : mesenchymal (1) cell ratio and gestational age (GA). 
 
 
Identification and characterization of epithelial and mesenchymal cells 
After three days in culture, cells isolated using trypsin digestion which stained positive 
for cytokeratin-18 and E-cadherin but negative for vimentin were identified as 
epithelial. Those isolated with collagenase treatment and staining positive for vimentin 
but negative for cytokeratin-18 and E-cadherin were identified as mesenchymal. In 
monolayer culture, epithelial cells appeared rounded and cuboidal, forming clusters 
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across the culture plate. Mesenchymal cells had a fusiform spindle shape with 
cytoplasmic pseudopodia. 
 
 
Effect of culture conditions, media and gestational age on cell proliferation 
Having demonstrated that proliferation of term epithelial cells on TCPS using serum-
free medium85 was similar that on collagen I (0.633±0.414 vs. 0.648±0.448; p=0.83), 
we performed all further experiments on TCPS, for cost and time reasons, and because 
the harvest of term mesenchymal cells was low. Proliferation of epithelial cells of 
preterm vs. term placental origin cultured under similar conditions in medium 1 did not 
show a statistically significant difference (p=0.30). However, preterm and term 
mesenchymal cells failed to proliferate on either surface. We therefore tested term 
epithelial and mesenchymal cells in three other media in an attempt to optimize 
mesenchymal-biased proliferation. Epithelial cell growth patterns and morphology were 
similar in all four media. Term epithelial proliferation (Figure 3A) was similar in 
serum-free media (media 1+2) and 10 % FBS-containing medium (medium 4) and 
highest in medium 3.The same results were found for preterm epithelial cell 
proliferation (medium 1: 0.082±0.72; medium 2: 0.166±0.124; medium 3: 0.827±0.675; 
medium 4: 0.254±0.186). For term epithelial cell proliferation statistical analysis 
showed that proliferation in medium 3 was highly significantly increased (p<0.001) 
compared with cell proliferation in media 1, 2 and 4. However, for preterm epithelial 
cell proliferation no significant difference was found between medium 3 and 4 (p=0.15), 
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but proliferation in medium 3 tended to be increased compared with medium 2 and 1 
(p=0.08). 
In the case of mesenchymal cells, medium 3 also gave the highest proliferation for both 
preterm (medium 1: 0.183±0.121; medium 2: 0.228±0.120; medium 3: 1.081±0.668; 
medium 4: 0.913±0.337) and term (Figure 3B) cells, followed by medium 4, which 
contained only 10 % FBS. Serum-free media 1 and 2 failed to stimulate mesenchymal 
proliferation (Figure 3B). Statistical analysis showed that proliferation of term 
mesenchymal cells in medium 3 was highly significantly increased (p≤0.001) compared 
with cell proliferation in media 1, 2 and 4; for preterm mesenchymal cell proliferation 
no statistical difference was detected between mediums 3 and 4 (p=0.7).  
Concerning the percentage proliferation at day 14, with media 3 and 4 preterm epithelial 
and mesenchymal proliferation was similar to, or slightly higher than, its term 
counterpart (Figure 4). 
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A  
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Figure 3. Proliferation of human amnion cells from term placenta (mean ± SD/2) in 
four different media (media 3 & 4 contained 10 % FBS): (A) Epithelial cells; (B) 
Mesenchymal cells. 
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Figure 4. Proliferation (%) of amnion epithelial and mesenchymal cells from preterm 
vs. term placenta after 14 days culture. 
 
 
Discussion 
To our knowledge this is the first report on the effect of varying culture conditions and 
media (± serum, and with growth factors in different concentrations) on the growth and 
proliferation of human amnion epithelial and mesenchymal cells. Our medium 3 elicited 
significantly higher term epithelial and mesenchymal proliferation rates than culture 
media previously described for amnion cells (primarily DMEM + 10 % FBS). 
Mesenchymal cells failed to proliferate without FBS, i.e. FBS contains a factor, as yet 
unidentified, which is essential for the induction of mesenchymal proliferation.  
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The strengths of our study are that we included a large number (n=42) of human amnion 
cell cultures, analyzed mesenchymal in addition to epithelial cells, and examined GA-
dependent proliferation. However, the proportion of preterm membrane cultures 
remained low as we had to exclude many cases with PROM: Garzetti et al.88 described 
decreased cell growth potential in PROM amnion culture. For this reason, we could not 
attribute statistical significance to our finding, in line with our hypothesis based on GA-
dependent apoptosis87, that percentage proliferation was slightly higher in amnion cells 
from preterm vs term placenta. However, our result agrees with the findings of both 
Terada et al.7, who reported that amnion cells harvested at elective cesarean section 
ceased to proliferate after 11 days in culture despite regular replacement of fresh 
medium and cytokines, and Casey and MacDonald6, who found that the capacity for 
interstitial collagen synthesis was greatest in amnion from pre-16 week pregnancies, 
after which it rapidly declined.  
A weakness of our study is that we tested cell proliferation only on TCPS and collagen I 
but not on other extracellular matrixes, some of whose proteins possess intrinsic growth 
factor or mitogenic activity89. The reason for using TCPS and the natural substrate, 
collagen, is that on starting our study we obtained just enough cells for two different 
experiments. 
Few data are available in the literature on human amnion cell growth. Shortcomings in 
previous studies have included failure to specify the number of cell cultures examined7, 
85, 90 or the exact GA of the amnion of origin7, thereby neglecting an important 
determinant of both viability and cell distribution: our study confirmed the histological 
evidence91 for a disproportionate increase during gestation of epithelial over 
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mesenchymal cells. Other shortcomings have been the use of term placenta only85, 90, 
analysis of epithelial cells only7, and failure to isolate epithelial and mesenchymal 
cells85, 90 - of particular importance given that cell preparations can vary enormously in 
epithelial:mesenchymal ratio, from 3:97 to 87:1392. 
Amnion cells in primary monolayer culture share several morphologic, biochemical, 
and enzymatic characteristics with cells in amnion tissue81. Culture is therefore a 
suitable technique for studying amnion cell proliferation with the long-term purpose of 
tissue repair in selected cases of PROM. We did not use amniotic fluid as a cell source 
for fetal tissue engineering93 because of maternal cell contamination94 and the presence 
of cells of different tissue origins95. 
The advantage of using heterologous human amnion cells for tissue repair is that 
amnion is readily and plentifully available. Human amnion epithelial cells also do not 
express the human leukocyte antigens (HLA)-A, -B, -C or -DR, suggesting that they do 
not induce immune rejection after allotranplantation7. The use of human heterologous 
amnion cells for engineered repair of PROM thus seems a promising strategy, after the 
ultimately unsuccessful experiments with alternative approaches, including 
amniopatch30, amniograft46, maternal blood clot patch29 and fibrin glue77. Maybe 
biodegradeable fibrin microbeads (FMB) as potent cell carriers96, 97 are useful to bring 
the amnion cells by injection to the rupture side and induce amnion cells to migrate into 
the whole and close it. In the pig skin dermal wound model FMB seemed to be very 
promising, as by day 3 only wounds which had been implanted with the combination of 
FBS + fibroblasts demonstrated accelerated healing and substantial formation of 
granulation tissue96. We are therefore planning further studies, in order to exam the 
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behavior and proliferation of human amnion cells on FMB and other extracellar 
matrixes and to evaluate the wound healing potential of human amnion cells. 
In conclusion, we have characterized human amnion epithelial and mesenchymal cells 
in culture, induced cell proliferation with different media, and found one medium which 
stimulated proliferation better than previously published media. We intend to use these 
data to evaluate the wound healing potential of human amnion cells by examining their 
behaviour and proliferation on fibrin microbeads and other extracellular matrixes, with 
the ultimate aim of engineering the tissue repair of PROM. 
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Abstract 
Objective: To compare ‘wound healing’ by human amnion epithelial and mesenchymal 
cells from preterm and term placenta using an in vitro lesion repair assay. 
Study design: Lesions were created in confluent monolayers of amnion epithelial and 
mesenchymal cells from preterm and term placentas. Repair was monitored by 
measuring lesion area and the response to potential stimulants (platelet derived growth 
factor, tumor necrosis factor α, fibrinogen and phorbol myristate acetate). Cell 
proliferation was detected using 5-bromodeoxyuridine staining. 
Results: Lesion repair was complete within 40 h in control epithelial cultures from 
preterm and term placenta but incomplete in mesenchymal cultures (preterm cells: 80%; 
term cells: 40%). Platelet derived growth factor, tumor necrosis factor α, fibrinogen, and 
phorbol myristate acetate did not accelerate repair in either cell type. 
Conclusion: An in vitro lesion repair assay revealed differences in lesion repair 
capacity between amnion epithelial and mesenchymal cells and between mesenchymal 
cells from preterm and term placenta. 
 
Key words: amnion epithelial and mesenchymal cells, preterm and term placenta, 
wound healing 
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Introduction 
Premature rupture of the membranes (PROM) occurs in approximately 1 % of all 
pregnancies and 30-40 % of preterm deliveries71. Both PROM and preterm birth carry a 
high risk of maternal morbidity and neonatal morbidity and mortality98. Several 
treatments for PROM in human fetal membrane models have been proposed, including 
amniopatch30, 99, 100, amniograft46, maternal blood clot patch29 and fibrin glue40, 77, but 
clinical studies have been few and success limited: none of these treatments have yet 
been introduced into clinical routine. 
Most studies have focused on the pathogenesis of PROM72, 101-103 but few have 
addressed the repair potential of the fetal membranes. Yet clinical experience supports 
the assumption that the fetal membranes are capable of self-repair: the incidence of 
PROM after routine midtrimester amniocentesis is very low74, 75 and spontaneous 
resealing after PROM is reported in 7.7 % to 9.7 % of cases24, 76. The aim of the present 
study was to investigate and compare the repair potential of amnion epithelial and 
mesenchymal cells from preterm and term placenta using an in vitro lesion repair assay 
with the ultimate objective of designing therapeutic strategies for PROM. 
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Material and methods 
 
Isolation and culture of amnion epithelial and mesenchymal cells  
Amnion tissues were collected immediately after elective cesarean section from five 
preterm (32-36 week) and four term (37-38 week) placentas with attached membranes 
from women without PROM, signs of infection or chromosomal abnormalities. Amnion 
and chorion laeve tissues were separated by blunt dissection81, 104, and the amnion was 
cut approximately 2 cm from the placental disc to avoid the ‘zone of altered 
morphology’82, 105. The samples were washed in phosphate buffered saline (PBS; 
Sigma, Buchs, Switzerland) to remove cellular debris and blood, then minced and 
treated four times with 0.25 % trypsin (Gibco BRL, Basel, Switzerland) for 15 min. The 
first digestion supernatant, consisting primarily of red blood cells, was discarded. 
Epithelial cells obtained during subsequent trypsinizations were pelleted by 
centrifugation at 1000 rpm for 5 min and resuspended in a basal medium comprising a 
1:1 mixture of Ham’s F-12 and Dulbecco’s minimal essential medium (Gibco) 
containing 10 % heat inactivated fetal bovine serum (FBS; Gibco), 100 U/ml penicillin 
(Gibco), and 100 μg/ml streptomycin (Gibco). Mesenchymal cells were isolated from 
the remaining amnion tissue after complete removal of epithelial cells (evaluated 
microscopically). The tissue was minced and incubated with 2 mg/ml collagenase A 
(Roche Diagnostics, Rotkreuz, Switzerland) at 37° C for 120 min. Dispersed 
mesenchymal cells were collected by centrifugation at 1000 rpm for 5 min. Epithelial 
and mesenchymal cell viability assessed by trypan blue dye exclusion was 97 %. Both 
cell types were cultured further in basal medium supplemented with 50 ng/ml epidermal 
growth factor (EGF; Sigma), 2.5 μg/ml insulin (Sigma), 5 μg/ml transferrin (Sigma), 
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and 0.1 ng/ml triiodothyronine (T3; Sigma) [‘supplemented basal medium’]. The cells 
were maintained in culture until confluence in a humidified atmosphere at 37° C and 5 
% CO2. 
 
Microscopy 
Samples were analyzed by phase contrast and fluorescence microscopy (Zeiss, Axiovert 
135, Oberkochem, Germany). The images were taken by a Hamamatsu CCD camera 
and processed using LeicaQ Win Image Analysis software (Leica Imaging System, Ltd., 
Cambridge, England, UK) and Photoshop version 5.0. Experiments were done in 
duplicate, and four fields of each sample were analyzed. 
 
In vitro lesion repair assay  
Cells were grown to confluence in 48-well plates (Nunclon delta, Nunc, D-65203 
Wiesbaden) in supplemented basal medium. Prior to assay they were challenged 
overnight with serum-free medium. The monolayer was lesioned using a ∼2 mm cell 
scraper without damaging the dish surface. Immediately post-lesion, parallel samples 
were incubated with either 100 ng/ml platelet-derived growth factor (PDGF; Sigma), 50 
ng/ml tumor necrosis factor α (TNFα; Sigma), 3 mg/ml fibrinogen (Sigma), or 50 ng/ml 
phorbol myristate acetate (PMA; Sigma) Lesion areas were imaged at 0 h, 16 h and 40 h 
and, after manual analysis using image processing software, calculated by subtracting 
the area in μm2 between the lesion edges from the area measured at 0 h. Values were 
expressed as a percentage of the 0 h area (100 %). 
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Cell proliferation assay 
To detect and quantify proliferating cells, 5-bromo-2′-deoxyuridine (BrdU) 
incorporation into cellular DNA was determined according to the manufacturers’ 
instructions (Sigma): 16 h post-lesion, the cells were incubated ± stimulating factors 
with 10 μM BrdU for 90 min at room temperature. They were then fixed in absolute 
methanol for 10 min at +4° C and air dried after removal. DNA was denatured by 
incubating the cells in 2 M HCl for 60 min at +37° C. The cells were further immersed 
in 0.1 M borate buffer, pH 8.5, to neutralize the acid. The buffer was changed twice in 
10 min. The cells were then washed 3 times in 10 min with PBS before being placed in 
a humidified chamber and incubated with anti-bromodeoxyuridine-fluorescein [diluted 
1:10 in PBS supplied with 0.1 % bovine serum albumin (BSA; Sigma)] overnight at 
4°C. After repeated washing the cells were analyzed by fluorescence microscopy. BrdU 
incorporation was quantified by calculating the percentage of BrdU positive cells both 
in the perilesional area and at the cell culture edge furthest from the lesion. 
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Results 
 
Repair of amnion epithelial and mesenchymal cells in monolayer cell cultures  
Epithelial and mesenchymal cells differed in repair potential. The control epithelial cell 
monolayer from preterm placenta was fully repaired within 40 h (Figure 1A). The cells 
appeared rounded and cuboidal, similar to their pre-lesion appearance, i.e. their 
structural integrity was maintained. Addition of PDGF, TNFα, and fibrinogen had no 
stimulant effect (Figure 1C), while PMA markedly increased lesion area over the test 
period. Term placenta epithelial cells gave similar results (Figures 1B and D). In 
mesenchymal cells from preterm and term placenta, repair at 40 h was incomplete (80 
% and 40 %, respectively; Figures 2A and B). Perilesional mesenchymal cells acquired 
a migratory phenotype with extension of lamellipodia and cytoplasmic protrusions in 
contrast to the spindle shaped cells within the confluent monolayer. Preterm 
mesenchymal cells had approximately twice the repair potential of their term 
counterparts; in neither case was repair stimulated by PDGF, TNFα, or fibrinogen 
(Figures 2C and D). PMA had the same effect as on preterm and term epithelial cells. 
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Figure 1. Timed phase contrast images of lesion areas (scale bar, 1 mm) in control 
amnion epithelial cells from preterm (A) and term (B) placenta show complete lesion 
repair within 40 hours. Timed lesion repair, expressed as the percentage of original 
lesion area (mean ± SD) of five preterm (C) and four term experiments (D), in control 
(open bars) and treated epithelial cultures show no acceleration in response to PDGF 
(diamond hatched bars), TNFα (hatched bars), fibrinogen (dotted bars), and PMA 
(closed bars). 
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Figure 2. Timed phase contrast images of lesion areas (scale bar, 1 mm) in control 
amnion mesenchymal cells from preterm (A) and term (B) placenta show 80 % and 40 
% repair, respectively, at 40 hours. Timed lesion repair, expressed as the percentage of 
original lesion area (mean ± SD) of five preterm (C) and four term (D) experiments in 
control (open bars) and treated mesenchymal cultures show an approximate 2-fold 
increase in lesion repair in preterm versus term cultures and no acceleration in response 
to PDGF (diamond hatched bars), TNFα (hatched bars), fibrinogen (dotted bars), and 
PMA (closed bars). 
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Amnion epithelial and mesenchymal cell proliferation 
In both epithelial and mesenchymal cells from preterm and term placenta, BrdU positive 
cells were detected in the perilesional area and at the culture edge (Figure 3A and B). 
PDGF, TNFα, and fibrinogen did not stimulate preterm epithelial proliferation (Figure 
3A) versus control; PDGF was even inhibitory. In contrast, mesenchymal incorporation 
of BrdU increased versus control in the presence of PDGF (2.5 %) and especially TNFα 
(5 %). In fact TNFα increased preterm mesenchymal cell proliferation by 100 %. BrdU 
positive cells were rare after the addition of fibrinogen, and absent in both epithelial and 
mesenchymal cultures after PMA. Term epithelial cell proliferation was approximately 
10% that of its preterm counterpart (control group; Figures 3A and B); it was similar to 
the control after the addition of PDGF, TNFα, fibrinogen and PMA (Figure 3B). BrdU 
incorporation by term mesenchymal cells was approximately 50 % greater (control 
group) than by their preterm counterparts (Figures 3A and B), and was not stimulated 
by any factor. However, both PDGF and TNFα increased proliferation in preterm 
mesenchymal cells. 
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Figure 3. BrdU positive amnion epithelial and mesenchymal cells from preterm (A) and 
term (B) placenta 16 hours after the lesion in control and treated cultures (mean 
percentage ± SD) of two preterm and two term experiments. Proliferating cells were 
detected in the perilesional area and at the culture edge (A and B). 
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Comment 
This study was performed to examine the repair potential of amnion epithelial and 
mesenchymal cells from preterm and term placenta and test the effect of potential 
proliferation stimulants. We found that epithelial and mesenchymal cells differed in 
repair potential, as did mesenchymal cells from preterm and term placentas, achieving 
80 % repair at 40 h versus 40 %, respectively. Thus mesenchymal cells from term 
placenta healed more slowly than their preterm counterparts. 
We found no enhancement of lesion repair after treatment with four potential stimulants 
of cell proliferation and migration: PDGF, TNFα, fibrinogen and PMA. No factor 
increased preterm epithelial proliferation versus control. However, both PDGF and 
TNFα stimulated preterm mesenchymal proliferation. This finding is inconsistent with 
the incomplete mesenchymal repair observed at 40 h in the stimulated and control 
groups. A possible explanation is that PDGF and TNFα did stimulate proliferation but a 
decrease in the size of the lesion could not be detected within our 40 h study period due 
to very long doubling time of amnion cells in culture (150-210 h86). However, PDGF 
and TNFα did not stimulate the proliferation of term mesenchymal cells, which was also 
approximately double that of preterm mesenchymal cells (control group). 
No data have previously been published on the repair capacity of isolated human 
amnion epithelial and mesenchymal cells from preterm and term placenta. Earlier 
studies focused either on organ cultures for evaluating the healing capacity of fetal 
membrane28 or on the repair kinetics of the FL human cell line106. The latter was 
established by HeLa cell contamination (American Type Culture Collection: 
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www.atcc.org), suggesting that the cell population used in the study was not precisely 
defined. 
To our knowledge ours is the first study of lesion repair by isolated amnion epithelial 
and mesenchymal cells using an in vitro lesion repair assay. In vitro characterization is 
an essential prerequisite for understanding the basic mechanisms by which healing 
occurs. The assay was conducted in primary monolayer cell cultures as these have been 
shown to share several morphologic, biochemical, and enzymatic characteristics with 
cells in amnion tissue81. Further study is now required using different extracellular 
matrix molecules. There are at least three mechanisms via which the extracellular 
matrix can regulate cell behaviour through specific morphogenetic signals: 1) the 
composition of the matrix itself; 2) synergistic interaction between matrix molecules 
and growth factors; and 3) cell surface receptors mediating adhesion to matrix 
components89. We also need to evaluate the effects of lesion type and size on amnion 
cell repair processes at different gestational ages. The present study is simply a first step 
towards characterizing the repair capacity of amnion epithelial and mesenchymal cells 
of different gestational age with a long-term view to their use in the development of 
new therapeutic strategies for PROM. 
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Abstract 
Objective: In this study, human preterm amnion cells were investigated in three-
dimensional (3D) cell-matrix culture systems in an attempt to design therapeutic 
strategies for preterm premature rupture of the membranes.  
Study design: 3D collagen I and fibrin cell containing biomatrices were created on a 
way that mimics the architecture of native amnion. Amnion mesenchymal cells were 
embedded in 3D matrices and epithelial cells were placed on top of these matrices. Cell 
viability and morphology were visualized by DiI-ac-LDL, F-actin and nuclear staining. 
Proteolytic activity of matrix metalloproteinases (MMPs) was investigated using 
gelatine zymography.  
Results: Preterm amnion epithelial and mesenchymal cells cultured in collagen I and 
fibrin matrices assume cell morphologies, similar to those observed in vivo. 
Mesenchymal cells were capable of remodelling collagen I, as seen by extensive 
volume contraction by 40 % at day 1 and 80 % at day 5. Matrix contraction was 
independent of the presence of epithelial cells, and could not be inhibited by GM6001 
and/or aprotinin. No contraction was observed in fibrin matrices over 8 days. The 
migratory response of mesenchymal cells cultured in 3D fibrin matrices supplemented 
with fibronectin was associated with specific activated MMP-9. 
Conclusion: 3D fibrin matrices might be useful in amnion cell tissue engineering 
including cell-matrix transplantation.  
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Introduction 
Preterm premature rupture of the membranes (PPROM) occurs in approximately 1 % of 
all pregnancies and is associated with 30-40 % of preterm deliveries. It is the leading 
identifiable cause of preterm delivery5. Both PPROM and preterm birth carry a high risk 
of maternal morbidity and neonatal morbidity and mortality98. Several treatments for 
premature rupture of the membranes (PROM) in human fetal membrane models have 
been proposed. The application of maternal blood clot patches has been recognized as a 
potential option for therapy of PPROM29. However, the intra-amniotic deposition of a 
mixture of platelets in fibrin cryoprecipitate called ‘amniopatch’30, 99, 100 as well as a 
trans-vaginally applied intracervical fibrin sealant40 have been only partially successful 
in treatment of PPROM. A recent single case report for treatment of PPROM refers to 
using a collagen plug in combination with additional fixation with fibrin glue 
adhesives46. Although the sealing was initially effective, PPROM reoccurred after two 
weeks. Despite their apparent potential, none of these treatments have been introduced 
into routine clinical use. Failure of those trials may have resulted from the lack of 
integration of the plugs at the site of regeneration and the lack of subsequent healing 
responses. Based on the literature, the healing responses after implantation of the plug 
strongly depend on recruitment of cells from adjacent native tissue. In addition, the 
healing process may be facilitated and accelerated by tissue specific cells provided 
within a biocompatible plug on/in which these cells can proliferate48, 107. 
The aim of this study was to investigate the behaviour of human amnion cells in three-
dimensional (3D) collagen I and fibrin matrices, with the ultimate objective to develop a 
clinically relevant cell-matrix system for treatment of PPROM. 
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Material and methods 
Isolation and culture of human preterm amnion epithelial and mesenchymal cells 
Preterm amnion epithelial and mesenhymal cells were isolated and cultured as described 
previously108. Amnion tissues were collected immediately after elective cesarean section 
from six preterm (28-36 week) placentas with attached membranes from women 
without PROM, signs of infection or chromosomal abnormalities. The main indications 
for the elective cesarean sections were preeclampsia, intrauterine growth retardation and 
placenta praevia. Amnion and chorion leave tissues were separated by blunt dissection81, 
104, and the amnion was cut approximately 2 cm from the placental disc to avoid the 
‘zone of altered morphology’82, 105. The samples were washed in phosphate buffered 
saline (PBS; Sigma, Buchs, Switzerland) to remove cellular debris and blood, minced 
and treated four times with 0.25 % trypsin (Gibco BRL, Basel, Switzerland) for 15 min. 
The first digestion supernatant, consisting primarily of red blood cells, was discarded. 
Epithelial cells obtained during subsequent trypsin treatments and were collected by 
centrifugation at 1000 rpm for 5 min and resuspended in a basal medium comprising a 
1:1 mixture of Ham’s F-12 and Dulbecco’s minimal essential medium (Gibco) 
containing 10 % heat inactivated fetal bovine serum (FBS; Gibco), 100 U/ml penicillin 
(Gibco), and 100 μg/ml streptomycin (Gibco). Mesenchymal cells were isolated from 
the remaining amnion tissue after complete (>98 %) removal of epithelial cells 
(evaluated microscopically). The tissue was minced and incubated with 2 mg/ml 
collagenase A (Roche Diagnostics, Rotkreuz, Switzerland) at 37° C for 120 min. 
Dispersed mesenchymal cells were collected by centrifugation at 1000 rpm for 5 min. 
Epithelial and mesenchymal cell viability as assessed by trypan blue dye exclusion and 
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was found to be over 97 %. Both cell types were cultured further in basal medium 
supplemented with 50 ng/ml epidermal growth factor (EGF; Sigma), 2.5 μg/ml insulin 
(Sigma), 5 μg/ml transferrin (Sigma), and 0.1 ng/ml triiodothyronine (T3; Sigma). This 
medium is further referred to as ‘supplemented basal medium’. The cells were 
maintained in culture until confluence in a humidified atmosphere at 37° C and 5 % 
CO2. 
 
Co-culture of preterm amnion epithelial and mesenchymal cells in three-
dimensional collagen I matrices  
The 3D collagen I matrices used for co-culture of embedded preterm amnion epithelial 
and mesenchymal cells were utilized to create a cell-matrix system that mimics the 
structure of native amnion (Figure 1). 1 x 104 preterm amnion mesenchymal cells were 
mixed with 100 µl neutralized collagen I solution (BD Biosciences, Bedford, MA, 
USA). The final concentration of collagen I solution was 2 mg/ml. Samples were placed 
in 96-well MicroWell® plates (Nunclon delta, Nunc, Wiesbaden, Germany). 
Polymerization was allowed to proceed for 15 minutes at 37º C. Subsequently, 1 x 104 
preterm amnion epithelial cells were added on top of the collagen I matrices. Cell-
matrix systems were cultured in ‘supplemented basal medium’ at 37º C, 5 % CO2, in a 
humidified atmosphere. 
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Assessment of global collagen I matrix contraction  
Eight experimental groups of collagen I matrices were examined as outlined in Table I. 
These eight experimental groups were performed using epithelial and mesenchymal 
cells of three different preterm amnion membranes. Mesenchymal cells were either 
embedded into 3D collagen I matrices (Group I, III, V, VII) or matrices containing 
mesenchymal cells were covered by epithelial cells (Group II, IV, VI, VIII). In some 
indicated cases GM6001 (an inhibitor of MMP-1, MMP-2, MMP-3, MMP-8 and MMP-
9; Chemicon, Juro Supply GmbH, Lucerne, Switzerland) and/or aprotinin (an inhibitor 
of serine proteases; Sigma, Switzerland) were mixed into the collagen I solution prior to 
polymerization at a final concentration of 10 µM and 50 μg/ml, respectively. Native 
cell-free collagen I matrices were used as controls. The size of 3D collagen I matrices 
was analyzed by phase contrast and fluorescence microscopy Leica DMIL (Leica, 
Glattbrugg, Switzerland) equipped with a Leica DC 300F digital camera (Leica, 
Glattbrugg, Switzerland). Collagen I matrix contraction was monitored daily and 
processed using a LeicaQ Win Image Analysis software (Leica Imaging System, Ltd., 
Cambridge, England, UK) and Photoshop®7.0 (Adobe Systems Inc., USA). The size of 
3D collagen I matrices were calculated by subtracting the matrix size in square 
micrometers from the size measured at t=0 (0 hours). Values were expressed as a 
percentage of the size at t=0 (100 %). 
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Groups of 3D 
collagen I 
matrices 
Mesenchymal 
cells 
Epithelial cells GM6001 
(10µM) 
Aprotinin 
(50μg/ml) 
I + - - - 
II + + - - 
III + - + - 
IV + + + - 
V + - - + 
VI + + - + 
VII + - + + 
VIII + + + + 
Control - - - - 
 
Table I. Experimental groups of 3D collagen I matrices. Mesenchymal cells were 
embedded into collagen I matrices (Group I, III, V, VII) or mesenchymal cells were 
embedded and epithelial cells were seeded on top of these matrices (Group II, IV, VI, 
VIII). In some indicated cases the matrices were incubated with 10 µM GM6001 
(Group III, IV, VII, VIII) and/or with 50 μg/ml aprotinin (Group V, VI, VII, VIII). 
Native cell-free collagen I matrices were used as control. 
 
Preparation of fibrin matrices 
Fibrin matrices were prepared according to standard protocols by mixing the following 
components to the final concentrations: 2 mg/ml fibrinogen (Fluka AG, Buchs, 
Switzerland) in 10 mM Tris bufferred saline, pH 7.4, 0.5 U/ml factor XIII (kindly 
provided by Baxter AG, Vienna, Austria), 2 NIH units/ml human thrombin (Sigma), 
and 2.5 mM CaCl2. Collagen I, fibronectin (Bioreba, Basel; Switzerland) or laminin-1 
(Sigma) were included at 20 µg/ml gel prior to initiation of fibrin polymerization by 
addition of thrombin (Sigma).  
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Co-culture of preterm amnion epithelial and mesenchymal cells in fibrin-based 
hydrogel matrices 
3D fibrin matrices were performed using epithelial and mesenchymal cells from three 
preterm amnion membranes. 2 x 104 preterm mesenchymal cells were suspended in 200 
µl fibrinogen solution containing different extracellular matrix molecules at 20 µg/ml 
prior to initiation of fibrin polymerization. Samples were placed in 8-well glass culture 
dishes (Nunc Lab-TekTMII Chamber slide system; VWR International AG, Dietikon, 
Switzerland). Polymerization induced by thrombin was allowed to continue for 5 min at 
37º C. Subsequently, the surface of 3D fibrin matrices were coated with either collagen 
I, fibronectin or laminin at 20 µg/ml and allowed to polymerize for another 1 h at 37º C. 
Thereafter, 2 x 104 preterm amnion epithelial cells were seeded on top of the 3D 
matrices (Figure 1). Cells-matrix systems were cultured for 8 days as described above. 
 
Epithelial cells
Mesenchymal cells
ECM
Medium
Amniotic fluid
Amnion membran 3D cell-matrix system
 
 
 
 
 
Figure 1. Schematic illustration of the natural term amniotic membrane (left). The 
schematic representation on the right depicts our cell-culture model that aims to mimic 
the cellular and structural composition of natural amnion. Preterm amnion mesenchymal 
cells were embedded in 3D matrices and epithelial cells were placed on top of these 3D 
matrices. 
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Cytochemical analysis 
To detect the uptake of 1,1’-dioctadecyl-3,3,3’3’-tetramethylindocarbocyanine-labeled 
acetylated LDL (DiI-ac-LDL; BTI Inc., Stoughton, MA), preterm amnion epithelial and 
mesenchymal cells were incubated with DiI-ac-LDL (2.4 µg/ml) at 37° C for 1 h. Cells 
were then fixed with 2 % paraformaldehyde for 10 min, washed 3x with PBS, 
permeabilized with 0.2 % Triton X-100 and incubated with rhodamine-labelled 
phalloidin (Molecular Probes, Eugene, OR) in order to visualize F-actin filaments. 
Finally, 4’6-diamidino-2-phenylindole, dihydrochloride (DAPI; Molecular Probes, 
Eugene, OR) was used to stain the nuclei of all cells. The fluorescently labeled cells 
were imaged with confocal laser scanning microscopy (Leica SP2, Leica, Glattbrugg, 
Switzerland). In some indicated cases, the data were further processed using Imaris 
software (Bitplane AG, Zurich, Switzerland).  
 
Gelatin zymography  
Gelatin zymography was used to investigate the proteolytic activities of MMPs 
expressed by preterm amnion mesenchymal cells embedded into 3D fibrin matrices. 
Collagen I, fibronectin or laminin-1 was included into fibrin matrices prior to 
coagulation. Native fibrin matrices without additional extracellular matrix molecules 
were used as controls. The culture supernatants were collected at day 1, 3, 5, and 7. The 
gelatinolytic activities of MMPs in cell-matrix culture supernatants were assessed as 
previously described109. Briefly, 10 µg of total proteins were applied onto 10 % SDS-
polyacrylamide gels copolymerized with 1 mg/ml gelatin and electrophoretically 
separated. Recombinant human MMP-2 and MMP-9 (Chemicon International, Inc., 
Temecula, CA) were used as gelatine zymography standards. The gels were 
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subsequently washed twice for 20 min with 2.5 % Triton X-100 to remove SDS and to 
allow the MMPs to renature before incubating in zymography buffer (20 mM Tris, pH 
8.0, 5 mM calcium chloride, 0.02 % sodium azide). The gels were incubated for 20 h at 
37° C with agitation. The zymographic gels were scanned using a Silverfast Expr1460 
scanner equipped with SilverFast v5.52r09 software (LaserSoft Imaging AG, Germany) 
and compared with each other. 
 
Statistical analysis 
Mean values and standard deviation are reported. Differences between two groups were 
analysed using the Mann-Whitney U test. The Kruskal-Wallis test was used to test the 
differences between several groups. Significance level was set on p<0.05. 
 
Results 
Preterm amnion mesenchymal cells contract collagen I matrices  
The use of amnion cell cultures in collagen I matrices was challenged by the extensive 
collagen I matrix contraction mediated by amnion mesenchymal cells. A significant 
decrease in the size of anchored collagen I matrices was detected over the course of 6 
days (p<0.001). In fact, the size of collagen I matrices was reduced by 40 % at culture 
day 1 and 80 % at culture day 5. This effect was independent of the presence of co-
cultured preterm amnion epithelial cells (Figure 2A). Furthermore, collagen I 
contraction could not be blocked by GM6001(10 µM) or/and by aprotinin (50 µg/ml) 
(Table II). In the absence of amnion cells, no change in collagen I matrix size was 
detectable (Figure 2A). Additionally, migration of living preterm amnion mesenchymal 
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cells out of zones of dense collagen I into zones of low collagen I concentrations was 
observed (Figure 2B).  
In summary, collagen I matrices significantly contract with increasing culture time, and 
preterm amnion mesenchymal cells are capable to remodel 3D collagen I matrices and 
to migrate out of 3D collagen I matrices. 
 
 
 Average of collagen I matrix size (%)  
Groups of 3D 
collagen I 
matrices 
Day 0 Day 1 Day 6 Matrix 
contraction 
I 99±1 58±5 14±1 yes 
II 99±1 57±11 15±1 yes 
III 99±1 66±5 25±7 yes 
IV 99±1 65±7 26±9 yes 
V 99±1 60±6 29±6 yes 
VI 99±1 61±8 28±6 yes 
VII 99±1 63±8 27±7 yes 
VIII 99±1 64±6 26±6 yes 
Control * 99±1 99±1 99±1 no 
 
Table II. Contraction of collagen I matrices mediated by preterm amnion mesenchymal 
cells (Group I and II) could not be blocked by 10 µM GM6001 and/or 50 µg/ml 
aprotinin (Group III, IV, V, VI, VII and VIII). In the absence of amnion cells (Control), 
no change in collagen I matrix size was observed. * indicates values that are 
significantly different from cell containing collagen I matrices. Matrix sizes are 
expressed as percentages of initial matrix size at day 0, and are given as mean ± SD of 
three experiments. 
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Figure 2. (A) Contraction of collagen I matrices mediated by preterm amnion 
mesenchymal cells. The size of collagen I matrices was reduced by 40 % at day 1 and 
80 % at day 5. This effect was independent of the presence of co-cultured preterm 
amnion epithelial cells. In the absence of amnion cells, no change in collagen I matrix 
size was observed. Matrix sizes are expressed as percentages of initial matrix size at day 
0, and are given as mean ± SD of three experiments. * indicates statistical significance 
of the condition ‘cell free-collagen I matrices’ vs condition ‘collagen I matrices 
containing mesenchymal and epithelial cells’ (p<0.001). Scale bar: 1mm. (B) Migration 
of living preterm amnion mesenchymal cells (arrowhead) from a zone of dense collagen 
I matrix (arrow) into zones lacking collagen I after contractions of the matrix. The 
dashed line indicates, approximately, the borders of contracted collagen I matrix. Living 
migrating cells were stained with DiI-ac-LDL. Scale bar: 250 µm.  
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Co-culture of preterm amnion epithelial and mesenchymal cells within native and 
modified fibrin hydrogel matrices  
As illustrated in Figures 3A-C fibrin matrix supplemented with fibronectin maintained 
the overall morphology of co-cultured amnion epithelial and mesenchymal cells. The 
overall cell morphology was visualised by co-staining for both F-actin and for cell 
nuclei. At culture day 2, amnion mesenchymal cells were sparsely distributed within the 
matrix and lacked prominent extensions (Figure 3A). In contrast, at culture day 8 
amnion mesenchymal cells displayed formation of the typically migratory phenotype 
with long cellular extensions (Figures 3B-C). As judged by DAPI staining, the number 
of mesenchymal cells was not significantly changed with increasing culture time 
(p=0.556). At culture days 2 and 8, the mean number of mesenchymal cells was 135 ± 7 
cells/0.5 mm2 and 140 ± 14 cells/0.5 mm2, respectively (Figure 3D). This finding 
indicates that preterm amnion mesenchymal cells in 3D fibrin matrices undergo 
differentiation rather than proliferation. Furthermore, fibrin matrices supplemented with 
fibronectin maintained the vitality of amnion cells. The vitality of amnion cells was not 
significantly changed over the time course of 8 days (p=0.444). At culture day 2, 87 % 
± 9 % of embedded mesenchymal cells (Figure 3D) and 89 % ± 7 % of epithelial cells 
were positive for DiI-ac- LDL uptake, determined as an indicator for cell-viability. 
Consistently at day 8, 84 ± 11 % of mesenchymal cells (Figure 3D) and 86 % ± 5 % of 
epithelial cells displayed viability. The amnion epithelial cell layer was formed on top 
of 3D fibrin matrices supplemented with fibronection. Amnion epithelial cells appeared 
similar to those observed in vivo (data not shown). Notably, no significantly decreased 
in the size of fibrin matrices was detected over the course of 8 days (p=0.222) (Figure 
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3E). Additionally, the overall morphology of amnion epithelial and mesenchymal cells 
cultured in fibrin matrices supplemented either with collagen I or laminin-1 was similar 
as in fibrin matrices supplemented with fibronectin (data not shown).  
Taken together, preterm amnion epithelial and mesenchymal cell morphologies in 3D 
fibrin matrices were found to be similar as observed in vivo. Amnion cells are highly 
viable and no significantly decrease in the size of fibrin cell-matrix systems was 
observed. 
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Figure 3. Morphology of preterm amnion epithelial and mesenchymal cells in 3D fibrin 
matrices supplemented with fibronectin. Overall cell morphology at culture days 2 and 
8 was visualized by staining for F-actin in combination with a DAPI nuclear stain. The 
reconstruction of the 3D system was performed using a stacked series of optical slices 
obtained by confocal laser scanning microscopy. (A) Amnion cell morphology 
visualized at culture day 2. Amnion mesenchymal cells were sparsely distributed 
without prominent extensions (M; arrow; star). The position of amnion epithelial cells is 
indicated (E; arrowhead). (B) Amnion cell morphology visualized at culture day 8. 
Amnion mesenchymal cells displayed a formation of typically migratory phenotype 
with cell extension (M; arrow; star). The position of amnion epithelial cells is indicated 
(E; arrowhead). (C) Morphology of preterm amnion mesenchymal cells at higher 
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magnification at culture day 8. Overall mesenchymal cell morphology was visualised by 
combining staining for F-actin (arrow) and DAPI staining for nuclei (arrowhead). (D) 
Amnion mesenchymal cells were highly viable as determined by Dil-ac-LDL uptake 
and the cell number determined by DAPI stain was not significantly changed over the 
time course of 8 days (p=0.556). Data represent evaluation of three images per culture 
condition. (E) No significantly decreased in the size of fibrin matrices was detected over 
the 8 days (p=0.222). Scale bars: A, 500µm; B, 500µm; C, 40µm. 
 
 
Preterm amnion mesenchymal cell migration within fibrin matrices supplemented 
with fibronectin is associated with activation of MMP-9 
The migratory response of preterm amnion mesenchymal cells cultured in fibrin 
matrices supplied with fibronectin was associated with increased levels of activated 
MMP-9. This activity was reduced after incubation with 10 µM GM6001. However, no 
activated MMP-9 was detected in cultures of preterm amnion mesenchymal cells within 
native fibrin matrices, or fibrin matrices containing collagen I or laminin-1. The inactive 
pro-forms of MMP-9 and MMP-2 could be detected in all cultures (Figure 4). 
In summary, fibronectin filled fibrin matrices were associated with upregulated MMP-9 
activation. This seems to be specific for fibronectin as fibrin matrices supplemented 
with laminin-1 or collagen I did not upregulate MMP-9 activation. 
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Figure 4. Comparison of gelatinoloytic activity of MMP-9 in cultures of preterm 
amnion mesenchymal cells cultured within 3D fibrin matrices. Fibrin matrices 
supplemented with fibronectin, collagen I or laminin-1 were assessed. Control cultures 
were prepared in native fibrin matrices. Increased levels of activated MMP-9 were 
detected in fibrin matrices containing fibronectin. Activity of MMP-9 was reduced after 
treatment with 10 µM GM6001. The positions of pro- and active forms of MMP-2 and 
MMP-9 are indicated as assessed by comparison with a MMP-2 and MMP-9 marker. 
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Comment 
Our study was performed to investigate the behavior of human preterm amnion 
epithelial and mesenchymal cells in 3D collagen I and fibrin matrices with the ultimate 
objective to develop a potential option for the treatment of PPROM patients based on 
tissue engineering. Tissue engineered transplants can be composed of two components, 
tissue-specific cells placed into a biocompatible scaffold on/in which these cells can 
proliferate. The scaffold material provides initial mechanical support and a template for 
three-dimensional organization47. The approach pursued here, relies on the design of a 
cell containing matrix that mimics the architecture of native amnion. The selection of 
cellular components of 3D matrices needs to be tissue specific. In our previous study, 
we have demonstrated that amnion epithelial and mesenchymal cells differ in their 
repair potential. Mesenchymal cells from preterm placenta healed more quickly than 
their term counterparts108. Consequently, in this study, the cellular components of the 
here developed cell-matrix transplants were amnion epithelial and mesenchymal cells 
from preterm placenta. Besides the selection of the cellular components that ultimately 
determined the function of such cell-matrix systems, an important feature of these 
systems, is the possibility of in situ application. Moreover, concerning the aim of this 
study, it is important that, such cell-matrix systems can be precisely administered via 
endoscopical methods to the ruptured site of the amnion membrane. Trying to meet this 
requirement, we have used 3D fibrin matrices as a scaffold matrix for isolated preterm 
amnion epithelial and mesenchymal cells. As outlined in this study, two interesting 
features of the 3D fibrin-matrix system were the refinement by the addition of 
extracellular matrix molecules that introduce additional adhesion sequences involved in 
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cell adhesion and/or migration, and specific matrix degradation by cell-associated 
proteases such as MMPs or serine proteases such as plasmin. We have demonstrated 
that preterm amnion epithelial and mesenchymal cells in modified 3D fibrin based cell-
matrix systems acquire their natural morphologies and displayed viability. In addition, 
in fibrin matrices supplemented with fibronectin, preterm amnion mesenchymal cells 
activated proteolytic programs of tissue repair, as specifically demonstrated by the 
activation of MMP-9. Moreover, fibronectin, here supplemented into native fibrin 
matrices, is an intrinsic component of clinical ‘fibrin glue’ formation. During clotting, 
plasma fibronectin incorporates to the fibrin network. Furthermore, the use of collagen I 
as a scaffold matrix was also investigated in this work. One limitation of this approach, 
as observed in this study, is contraction and consequently size reduction of collagen I 
matrices in vitro. In vivo, such a size reduction would inevitably induce failure of the 
implant followed by clinical consequences. According to the literature, control of the 
contraction and organization of cells and matrix, can be critical for successfully creating 
tissue engineered grafts110. Unfortunately, these aspect cannot be easily predicated at the 
design of cell-containing collagen I matrices. In contrast to the collagen I matrix-cell 
systems, no decrease in the size of fibrin cell-matrix systems was observed over the 
time course of one week. Related to this data, one might speculate that such fibrin based 
cell-matrix systems may be useful in amnion cell transplantation. By virtue of fibrin’s 
biological characteristics, such an implant could seal the membrane leak instantly. 
Subsequently, the fibrin clot may be remodelled into native membrane tissue by amnion 
cells provided in the matrix as well as by surrounding amnion cells. These fibrin based 
cell-matrix systems should induce only a low immunological response. First, the fibrin 
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matrix is physiologically and therapeutically relevant. It is widely applied in surgery as 
sealant and adhesive, and when formed from pure fibrinogen, represents a highly 
defined substrate. Secondly, human amnion epithelial cells do not express any of the 
leukocyte antigens (HLA)-A, -B, -C or –DR7, suggesting amnion tissue is a promising 
cell source for a variety of tissue engineering applications including amnion cell 
transplantation. Recently, successful xenotransplatations have been reported with 
human amnion epithelial cells in the spinal cord of monkeys111. Furthermore, different 
clinical studies confirmed that amnion material effectively facilitates epithelialization, 
can maintain normal cellular phenotypes, and reduce inflammation and scarring. Many 
studies are ongoing to investigate and use this unique feature of amniotic membranes as 
a prerequisite for tissue engineering112. Although the data presented here is promising, 
further studies must be undertaken to investigate the response of amnion cell-based 
tissue engineered grafts to more complex multifactorial in vivo environment. 
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In the present thesis, a strategy to develop a potential option for the treatment of 
PPROM patients based on a tissue engineering approach was proposed. Tissue 
engineered transplants can be composed of two components, tissue-specific cells placed 
into a biocompatible scaffold on/in which these cells can proliferate. The scaffold 
material provides initial mechanical support and a template for three-dimensional 
organization. The approach pursued here, relies on the design of a cell containing matrix 
that mimics the architecture of native amnion. The selection of cellular components of 
3D matrices needs particular attention on a issue. Further issues include establishment 
of reproducible methodology that permits to collect and expand human amnion 
epithelial and mesenchymal cells from preterm and term placenta (Chapter 2) as well as 
investigation of their repair potential in vitro (Chapter 3). In brief, it was demonstrated 
that the repair potential of human amnion epithelial and mesenchymal cells as well as 
their reaction towards different proliferating stimulants depends on the gestational age. 
Therefore, this thesis provides experimental data that supports the use of preterm 
amnion cells for the creation of cell-matrix transplants. This correlates with findings 
showing that, other characteristics related to the functional and anatomical integrity of 
the fetal membranes, like tensile strength and ECM composition have meanwhile also 
shown to be gestational age dependent113. Notably, according to the experience made in 
the course of this thesis, the cultivation of amnion cells can be difficult and may result 
in insufficient cell viability and cell number. One of the basic step in preparing human 
amnion cell cultures is collection of primary amnion tissue. It is very important to 
exclude membranes with any signs of PROM, infections, fetal chromosomal 
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abnormalities, intrauterine growth retardation , and intrauterine fetal death. This largely 
affected the viability, survival and proliferation rates of amnion cells. Besides these 
limitations, the gestational ages can also negatively affect the proliferation potential, 
especially of term amnion epithelial cells (Chapter 2).  
Another basic question that occurred during this work, concerns the selection of the 
scaffold matrix. Besides the selection of the cellular components that ultimately 
determined the function of such cell-matrix systems, an important feature of these 
systems, is the possibility of in situ application. Moreover, concerning the aim of this 
thesis, it is important that, such cell-matrix systems can be precisely administered via 
endoscopical methods to the ruptured site of the amnion membrane. Trying to meet this 
requirements, 3D fibrin matrices were used as a scaffold matrix for isolated preterm 
amnion epithelial and mesenchymal cells. As outlined in this thesis, an interesting 
refinement of the 3D fibrin-matrix system could be the addition of peptide sequences 
involved in cell adhesion and/or migration, and being degradable by cell-associated 
proteases such as MMPs or serine proteases such as plasmin. It was demonstrated, that 
preterm amnion epithelial and mesenchymal cells in modified 3D fibrin based cell-
matrix systems acquire their natural morphologies and displayed viability (Chapter 4). 
Beside the modification of fibrin matrices by admixtures of cell adhesions factors, as 
shown in this thesis, their further design improvements could be performed by 
exogenous admixture of growth factors. These bioactive molecules are produced by the 
cells themselves, but can as well be added exogenously to such cell-matrix systems to 
enhance their integration at the site of regeneration and also to induce stronger and more 
specific healing responses. Some promising factors could be PDGF and TNFα, that 
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have been found to increase the proliferation of preterm amnion mesenchymal cells 
(Chapter 3). Furthermore, the use of collagen I as a scaffold matrix was also 
investigated in this work. Limitation of this approach, as observed in Chapter 4, include 
contraction and consequently size reduction of collagen I matrices in vitro. In vivo such 
size reduction would inevitably induce failure of the implant followed by clinical 
consequences. According to the literature, control of the contraction and organization of 
cells and matrix, can be critical for successfully creating tissue engineered grafts110. 
Unfortunately, these aspect cannot be easily predicated at the design of cell-containing 
collagen I matrices. In contrast to the collagen I matrix-cell systems, no decrease in size 
of fibrin cell-matrix systems was observed over the time course of one week. Related to 
this data, one might speculate, that such fibrin based cell-matrix systems may be useful 
in amnion cell transplantation. By virtue of fibrin’s biological characteristics, such an 
implant could seal the membrane leak instantly. Subsequently, the fibrin clot may be 
remodeled into native membrane tissue by amnion cells provided in the matrix as well 
as by surrounding amnion cells. These fibrin based cell-matrix systems may represent a 
novelty in therapy of PPROM. However, these data are clearly preliminary and have to 
be confirmed by exposure of amnion cell-based tissue engineered grafts to more 
complex multifactorial in vivo conditions. Such an in situ delivery has not been 
investigated yet. One of the major problems in the design of an in vivo study includes 
the selection of appropriated animal models. Based on the literature only non-human 
primates closely resemble the human situation in terms of size, placentation and 
reproductive biology. Such future animal experiments should be undertaken in order to 
investigate the impact of a spontaneous cell migration and population on the formation 
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of tissue engineered constructs. This course of action strongly depends on the ability of 
cells to migrate across this provisional matrix as well as on their capacity to actively 
remodel their environment48, 114. An additional aspect to be considered for in vivo 
application of these cell-matrix systems is the potential induction of immunological 
responses. According to the findings in the literature, these fibrin based cell-matrix 
systems induce only a low immunological response. First, the fibrin matrix is 
physiologically and therapeutically relevant. It is widely applied in surgery as sealant 
and adhesive, and when formed from pure fibrinogen, represents a highly defined 
substrate. Secondly, human amnion epithelial cells do not express any of the leukocyte 
antigens (HLA)-A, -B, -C or -DR7 suggesting amnion tissue as a particular promising 
cell source for a variety of tissue engineering applications including amnion cell 
transplantation. Recently, successful xenotransplatations have been reported with 
human amnion epithelial cells in the spinal cord of monkeys111. Furthermore, different 
clinical studies confirmed that amnion material effectively facilitates epithelization, can 
maintain normal cellular phenotypes, reduce inflammation and scarring. Many studies 
are undergoing to investigate and use this unique feature of amniotic membranes as a 
prerequisite for tissue engineering112. Besides the promising observations, this issue 
needs to be well investigated before use in clinical applications. The results presented in 
this thesis may be only a beginning to gain insight into this poorly studied issue of fetal 
membrane repair. Although, the interest in fetal membrane repair was stimulated by the 
increased application of invasive fetal procedures, especially fetoscopy and fetal 
surgery, resulting in significant incidence in iatrogenic PPROM. Fetal membranes still 
remain the Achilles’ heel of these procedures. A better understanding of biology of fetal 
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membrane repair on a cellular, enzymatic as well as genetic level, may offer the 
prospect of developing tissue engineering and/or pharmacological means to modulate 
fetal membrane repair in order to limit the clinical consequences of spontaneous or 
iatrogenic PPROM.  
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